

# **EXHIBIT A**

## **Curriculum vitae of Hans Christian Korting**

Date and place of birth, parents:	Born on March 21, 1952 in Tübingen as the only son of the then scientific assistant Dr. Günter Waldemar Korting and his wife Johanna Herta Korting, born Kühnert
Nationality:	German
Religion:	Roman Catholic
Marital status:	married to Prof. Dr. phil. nat. Monika Schäfer-Korting, born Schäfer from Gießen, pharmacist, Chairwoman of the Chair of Pharmacology at the Faculty of Pharmacy of Freie Universität Berlin, since April 25, 1980
Children:	Sabine Denise Michaela, born September 10, 1985 Christina Maria Ursula, born September 12, 1987
Languages:	Fluency in English; Latin, French
Health status:	No limitations
1958 - 1962	Primary school, up to 1961 Uhlandschule in Tübingen, thereafter at Leibniz-Schule in Mainz
1962 - 1970	Staatliches Gutenberg-Gymnasium Mainz (modern languages branch, English for 9 years, Latin for 7 years and French for 3 years)

June 1, 1970	Certificate of unrestricted university study capability (Abitur), Staatliches Gutenberg-Gymnasium Mainz; average mark: 1.0
1970 - 1976	Study of medicine at Johannes-Gutenberg-Universität Mainz (5 pre-clinical half-year terms, 6 clinical half-year terms). During the entire study period immaterial scholarship by Studienstiftung des Deutschen Volkes
October 6, 1971	Scientific pre-examination (mark: very good)
March 23, 1973	Medical pre-examination (mark: very good)
July 8, 1976	Medical examination (mark: very good)
1976 - 1977	Medical assistant: 4 months each at 2nd Medical Department of Johannes-Gutenberg-Universität Mainz, Department of Pathology of Albert-Ludwigs-Universität Freiburg and Department of Surgery of Technische Universität München
January 26, 1977	Doctorate in Medicine by Medical Faculty of Johannes-Gutenberg-Universität Mainz; (mark: magna cum laude)
January 26, 1977	Exam of the Educational Commission for Foreign Medical Graduates (ECFMG) of the USA
October 1, 1977	Certified Physician (Approbation als Arzt)
1977 - 1979	Military Service as Medical Officer of the German Army (Bundeswehr)
November 1, 1977 - October 31, 1978	Residency in Internal Medicine at the Medical Department (Head: Dr. W. Voelpel) of Bundeswehr-Zentralkrankenhaus in Koblenz
November 1, 1978 -	Residency in Medical Microbiology and Infection

October 31, 1979	Epidemiology in the Department of Bacteriology and Mycology (Head: Prof. Dr. Dr. M. Bierther) of the Institut für Wehrmedizin und Hygiene - Ernst-Rodenwaldt-Institut - in Koblenz (both as a Lieutenant in the Medical Staff)
September 7, 1978	Visa Qualifying Examination of the ECFMG of the USA
October 7, 1980	Major of Reserve in the Medical Staff, appointment by Bundesminister der Verteidigung
1979 - today	Department of Dermatology and Allergology of Ludwig-Maximilians-Universität München
November 1, 1979	Appointment as full-time auxiliary scientific assistant
December 1, 1979	Appointment as Academic Counsellor
December 14, 1983	Specialist of Dermatology and Venereology by Bayerische Landesärztekammer
January 24, 1985	Specialist of Allergology by Bayerische Landesärztekammer
June 1, 1985	Acting Senior Consultant
December 4, 1985	Postdoctoral thesis in Dermatology and Venereology (Zuerkennung der Lehrbefähigung für das Fach Dermatologie und Venerologie und Verleihung des akademischen Grades eines Dr. med. habil.) by the Medical Faculty of Ludwig-Maximilians-Universität München
January 28, 1986	Appointment as Senior Lecturer (Erteilung der Lehrbefugnis und des Rechtes zur Führung der Bezeichnung Privatdozent) by Bayerischer Staatsminister für Unterricht und Kultus

April 1, 1986	Appointment as life-tenured Academic Counsellor on probation
December 11, 1987	Certificate on competence in radiation protection (Bescheinigung über Fachkunde und Kenntnisse im Strahlenschutz in der Therapie mit Röntgenstrahlen, Gamma-Bestrahlungseinrichtungen, Beschleunigern und beim Umgang mit umschlossenen radioaktiven Stoffen) by Gesellschaft für Strahlen- und Umweltforschung mbH, München
December 12, 1987	Appointment as life-tenured Academic Counsellor
1989	Member of Editorial Board of <i>mycoses</i> , more recently editor and finally Editor-in-Chief
June 1, 1990	Appointment as life-tenured Senior Academic Counsellor
August 30, 1990	Paul-Gerson-Unna-Preis (in half, together with Abeck) by Deutsche Dermatologische Gesellschaft
March 27, 1992	Appointment as extra-ordinary Professor by Bayerischer Staatsminister für Unterricht, Kultus, Wissenschaft und Kunst
June 18, 1993	Certificate on Laser Safety (Bescheinigung über die Teilnahme am Kurs Laser in der Medizin zum Erwerb der Sachkunde als Laserschutzbeauftragter nach Unfallverhütungsvorschrift "Laserstrahlung") by Institut für Lasertechnologien in der Medizin, Ulm
1994	Editorial Board Member <i>Skin Pharmacology and Physiology</i>
September 30, 1994	Forschungs-Förderungspreis of Deutschsprachige Mykologische Gesellschaft

December 7, 1994

End of reserve duty training at LANDCENT  
NATO-Headquarters in Heidelberg

1995

Co-founder and Vice-Chairman of Gesellschaft für  
Dermopharmazie

March 2, 1995

Appointment as Lieutenant Colonel of the Medical  
Staff of the Reserve by Bundesminister der  
Verteidigung

1999

Appointment as life-tenured Academic Director

2005

Secretary of Deutschsprachige Mykologische  
Gesellschaft (previously Chairman and Vice-  
Chairman)

Munich, March 30, 2007

---

## **Information on the researcher**

### **Status:**

Akademischer Direktor, Klinik und Poliklinik für Dermatologie und Allergologie der Ludwig-Maximilians-Universität, Frauenlobstraße 9-11, D-80337 München  
Telefon: 0049-89-5160-6203, Telefax: 0049-89-5160-6204  
e-mail: Hans-Christian.Korting@lrz.uni-muenchen.de

### **Special qualifications:**

Dermatologist and Allergologist

### **Special qualification for drug research:**

More than 2 years' experience in the field of conducting clinical trials as responsible researcher, i.e. Leiter der klinischen Prüfung according to Arzneimittelgesetz of the Federal Republic of Germany; more than 40 clinical drug trials published over a period of about two decades.

### **Fields of interest:**

Treatment or prophylaxis of diseases of the skin and bordering mucosal surfaces, in particular cancerous and inflammatory diseases may they be caused by microorganisms or not, primarily tinea and candidosis, atopic eczema, psoriasis vulgaris, seborrhoeic eczema; wound healing; mycoses of inner organs.

### **Related activities:**

Secretary and Past-President of Deutschsprachige Mykologische Gesellschaft (German-speaking Society for Medical and Veterinary Mycology),  
Deputy Chairman of Gesellschaft für Dermopharmazie (Society for Dermopharmacy),  
Head of the Committees on Quality Assurance and Therapy of Deutsche Dermatologische Gesellschaft (German Society for Dermatology: „DDG“),  
Editor/Co-Editor/Board Member of a variety of scientific journals including mycoses, JDDG, American Journal of Clinical Dermatology, Skin Pharmacology and Applied Skin Physiology, International Journal of Cosmetic Science.

### **Fields of activity:**

- Identification of medical needs oriented at potential indications for drugs at large as well as
- Identification of indications for rational use of active compounds and their preparations in the fields of dermatology and mycology
- Analysis of physiological and pathophysiological pathways in man with the aim of identification of drug targets and corresponding development of small molecules: signal transduction in the epidermis in non-infectious inflammatory skin disease and development of sphingosine-1-phosphate as an example (European patent)
- Identification of relevant macromolecules to be considered useful as drugs and their production using bio- and gene technology
- Formulation of drugs for topical use on the basis of known active compounds using drug carrier systems and consideration of corresponding changes in the molecular structure (collaboration in a new Forschergruppe, or research group supported by Deutsche Forschungsgemeinschaft or German Research Foundation, headed by my wife (Prof. Dr. phil. nat. Monika Schäfer-Korting, LS Pharmakologie, Fachbereich Biologie, Chemie und Pharmazie der Freien Universität Berlin, Königin-Luise-Straße 2-4, D-14195 Berlin). The topical glucocorticoid prednicarbate may serve as a prime example.
- Pharmacokinetics of systemic and topical drugs in vitro, ex vivo and in vivo: e.g. uptake of active compounds in dependence on the formulation and metabolism in keratinocytes in vitro, reconstructed human epidermis ex vivo and cutaneous absorption in man

- Pharmacodynamics: influence of active compounds on model diseases ex vivo, e.g. influence of topical antimycotic agents in various formulations – econazole serving as a prime example – in human mucocutaneous candidoses ex vivo and trials in human volunteers such as UV-erythema testing for treatment and prophylaxis of UV-induced skin disease
- Pharmacotoxicology: influence of active compounds on human keratinocytes and fibroblasts in vitro, on reconstructed human epidermis ex vivo and human skin, in particular investigation of skin thinning using 20 MHz sonography to identify antiinflammatory agents with the drawback of skin atrophy as it is found with conventional potent topical glucocorticoids
- Clinical trials, in particular addressing the systemic or topical use of active compounds and formulations for atopic eczema and tinea pedis, tinea corporis, tinea unguium and mucocutaneous candidosis as well as seborrhoeic eczema, in particular use of bi-lateral atopic eczema of the flexures of the upper extremities for intraindividual comparison of antiinflammatory agents for eczema

**References:**

For details see the enclosed selected reference list of Books, Original Communications and Review Articles.

Last update: March 2007



## **List of scientific publications**

<u>Doctoral thesis</u>	2
<u>Post-doctoral thesis (Habilitationsschrift)</u>	2
<u>Monographs</u>	3
<u>Contributions to text- and handbooks</u>	5
<u>Original communications</u>	7
<u>Case reports</u>	30
<u>Review articles</u>	38

### **Doctoral thesis**

Korting HC:

Mehrfachfrakturen der oberen Extremität (Mainz 1977)

### **Post-doctoral thesis (Habilitationsschrift)**

Korting HC:

Wirksamkeit und Verträglichkeit neuer  $\beta$ -Lactam-Antibiotika vom Typ der Cephalosporine bei der Gonorrhoe – Untersuchungsmethoden in vitro und in vivo und ihre Ergebnisse (München 1985)

## Monographs

1. Schäfer-Korting M, Korting HC, Mutschler E (1985) Pharmakokinetik oraler Antimykotika. Schattauer, Stuttgart, New York
2. Korting HC (1987) Cephalosporin-Therapie der Gonorrhoe. Karger, Basel, München, Paris, London, New York, New Delhi, Singapore, Tokyo, Sydney (MP, Habilitationsschrift)
3. Nolting S, Korting HC (Hrsg) (1989) Onychomykosen. Topische Antimykotika-Therapie. Springer, Berlin, Heidelberg, New York  
Englische Ausgabe: (1990) Onychomycoses. Local Antimycotic Treatment. Springer, Berlin, Heidelberg, New York  
Spanische Ausgabe: (1991) Onicomycosis. Tratamiento antimicótico local. Springer, Berlin, Heidelberg, New York
4. Gschnait F, Korting HC, Stary A (1990) Sexuell übertragbare Erkrankungen. Springer, Wien, New York  
(Eigene Beiträge: 42 Gonorrhoe, 43 Ulcus molle, 44 Lymphogranuloma inguinale, 45 Granuloma venereum, 47 Mykoplasmen-Infektionen, 48 Gardnerella-, Bacteroides- und Mobiluncus-Infektionen: Bakterielle Vaginose, 71 Trichomonas vaginalis-Infektionen, 72 Giardia lamblia- und Entamoeba histolytica-Infektionen: Das Gay-Bowel-Syndrom)
5. Braun-Falco O, Korting HC (Hrsg) (1990) Hautreinigung mit Syndets. Springer, Berlin, Heidelberg  
Englische Ausgabe (1992): Skin Cleansing with Synthetic Detergents. Springer, Berlin, Heidelberg
6. Braun-Falco O, Korting HC, Maibach HI (Eds) (1992) Liposome Dermatics. Springer, Berlin, Heidelberg
7. Korting HC, Maibach HI (Eds) (1993) Topical Glucocorticoids with Increased Benefit/Risk Ratio. Karger, Basel, New York
8. Plewig G, Korting HC (Hrsg) (1995) Fortschritte der praktischen Dermatologie und Venerologie, Bd 14. Springer, Berlin, Heidelberg, New York

9. Korting HC (1995) Dermatotherapie. Springer, Berlin, Heidelberg, New York  
Tschechische Ausgabe (zusammen mit Arenberger P) (1998): Dermatologická terapie. Springer, Prag
10. Korting HC, Sterry W (Hrsg) (1997) Diagnostische Verfahren in der Dermatologie. Blackwell, Berlin (tschechische Ausgabe in Vorbereitung)
11. Korting HC, Schäfer-Korting M (Eds) (1999) The Benefit/Risk Ratio: A Handbook for the Rational Use of Potentially Hazardous Drugs. CRC Press, Boca Raton
12. Korting HC, Gottlöber P, Schmid-Wendtner M-H, Peter R-U (1999) Ultraschall in der Dermatologie - Ein Atlas. Blackwell, Berlin
13. Korting HC, Callies R, Reusch M, Schlaeager M, Schöpf E, Sterry W (Hrsg) (2000) Handbuch Dermatologische Qualitätssicherung: Leitlinien und Empfehlungen, 1. Aufl. Zuckschwerdt, München, Bern, Wien, New York (2. Aufl. 2001)
14. Braun-Falco O, Gloor M, Korting HC (Hrsg) (2000) Nutzen und Risiko von Kosmetika. Springer, Berlin, Heidelberg, New York
15. Korting HC, Sterry W (Hrsg) (2001) Therapeutische Verfahren in der Dermatologie. Blackwell, Berlin
16. Korting HC, Kreuter T, Schäfer-Korting M (Hrsg) (2007) Enzyklopädisches Lexikon der Dermopharmazie. Springer, Berlin, Heidelberg, New York (in Vorbereitung)

## Contributions to text- and handbooks

1. Korting HC (1987) Dermatologie. In: Thomas C (Hrsg) Internationales Lehrbuch für Pharmaberater. Schattauer, Stuttgart, New York 12.1-31a
2. Korting HC (1987) Mykologie. In: Thomas C (Hrsg) Internationales Lehrbuch für Pharmaberater. Schattauer, Stuttgart, New York 13.1-21
3. Schäfer-Korting M, Korting HC (1989) Skin blisters and skin windows: an access to total and free drug concentrations in the skin. In: Maibach HI, Lowe HJ (Eds) Models in Dermatology 1989. Karger, Basel, München pp 45-63
4. Braun-Falco O, Korting HC (1991) Syndets in the Treatment of Atopic Eczema. In: Ruzicka T, Ring J, Przybilla B (Eds) Handbook of Atopic Eczema. Springer, Berlin, Heidelberg, New York pp 356-363
5. Korting HC (1991) Allgemeine Mykologie: Pilze. In: Hahn H, Falke D, Klein P (Hrsg) Medizinische Mikrobiologie. Springer, Berlin, Heidelberg, New York S 851-859
6. Korting HC (1991) Spezielle Mykologie: Pilzkrankungen. In: Hahn H, Falke D, Klein P (Hrsg) Medizinische Mikrobiologie. Springer, Berlin, Heidelberg, New York S 860-880
7. Korting HC, Czarnetzki BM (1992) Bakterielle Infektionen In: Czarnetzki BM, Kerl H, Sterry W (Hrsg) Dermatologie und Venerologie mit Repetitorium. De Gruyter, Berlin, New York S 64-79
8. Korting HC (1993) Fungal Infections of the Vulva and Vagina. In: Elsner P, Martius J (Eds) Vulvovaginitis. Marcel Dekker, New York, Basel, Hongkong pp 129-158
9. Abeck D, Korting HC (1993) Ulcus molle: Interaktion von Erreger und Wirt bei einer Genitalulkuskrankheit In: Macher E, Bröcker E-B, Kolde G (Hrsg) Jahrbuch der Dermatologie 1992/93. Biermann, Zülrich S 99-106
10. Korting HC, Ollert MW (1994) Lectin Specificities Relevant to the Medically Important Yeast *Candida albicans*. In: Doyle R, Slifkin M (Eds) Lectin microbe interactions. Marcel Dekker, New York pp 173-190

11. Schmid M-H, Korting HC (1995) Liposomes as penetration enhancers and controlled release units. In: Smith E, Maibach HI (Eds) Percutaneous penetration enhancers. CRC Press, Boca Raton pp 323-333
11. Gottlöber P, Korting HC (1997) Mykosen in der Dermatologie - Differentialdiagnose und Therapie In: Jehn U (Hrsg) Klinische Mykologie. Leitfaden für die inter-disziplinäre Praxis. Ecomed, Landsberg S 45-75
12. Korting HC, Schäfer-Korting M (1999) Topical liposome drugs. In: Korting HC, Schäfer-Korting M (Eds) The Benefit/Risk Ratio: A Handbook for the Rational Use of Potentially Hazardous Drugs. CRC Press, Boca Raton pp 333-357
13. Schmid-Wendtner M-H, Korting HC (2000) Dermatologie. In: Scriba PC, Pforte A (Hrsg) Taschenbuch der medizinisch-klinischen Diagnostik, 73. Aufl.. Springer, Berlin S 863-877
14. Schaller M, Korting HC (2000) Mycoses of the skin and mucosal surfaces. In: Fritsch P (Ed) White Book. Dermatology and Venereology in Europe. European Dermatology Forum, Innsbruck
15. Korting HC (2002) Haut- und Schleimhaut-Kandidosen: Einsichten in die Pathogenese schaffen neue Optionen für die Therapie und Prophylaxe. In: Konz B, Plewig G (Hrsg) Fortschritte der Dermatologie. Ein Rückblick auf 50 Jahre. Steinkopff, Darmstadt S 103-112
16. Herzinger T, Korting HC (2002) Dermatologische Erkrankungen. In: Schmailzl KJG, Hackelöer BJ (Hrsg) Schwangerschaft und Krankheit. Wechselwirkung – Therapie – Prognose. Blackwell, Berlin S 491-499

## Original communications

1. Korting HC, Stür D, Sulzbacher F (1980) Use of a Transport Medium in the Search for Salmonella Carriers - is it Worthwhile? *Med Microbiol Immunol* 168:149-151
2. Korting HC., Sulzbacher F (1980) Häufigkeit und Spezieszugehörigkeit von Bakterien des Genus Salmonella bei Bundeswehrangehörigen. Zugleich ein Beitrag zur Frage der rationellen Salmonellenträger-Diagnostik. *Med Welt* 34:1205-1208
3. Korting HC, Haag R (1980) Zur gegenwärtigen Empfindlichkeit von N. meningitidis gegen Penicillin G in vitro. Eine Untersuchung an 82 frischen Keimträgerstämmen von Bundeswehrangehörigen. *Zentralbl Bakt Hyg, I. Abt. Orig. A.* 248:129-133
4. Röhl R, Korting HC, Thönes K (1980) Dynamik des Rachenträgers von  $\beta$ -hämolisierenden Streptokokken der Gruppen A, B, C und G bei Soldaten. *Wehrmed Monatsschr* 24:9-13
5. Korting HC (1981) Untersuchungen und Überlegungen zum Meningokokken-trägersum bei jungen Soldaten unter besonderer Berücksichtigung seiner Dynamik. *Wehrmed Monatsschr* 25:65-81
6. Korting HC (1981) Gonococcal Carriage in the Throat – No Common Finding Anyway? Absence of Neisseria gonorrhoeae in the Pharynxes of 158 Repeatedly Swabbed Young Men. *Dermatologica* 163:249-254
7. Braun-Falco O, Korting HC, Konz B (1981) Histological and Cytological Criteria in the Diagnosis of Malignant Melanomas by Cryostat Sections. *Virchows Arch Pathol Anat* 393:115-121
8. Schäfer-Korting M, Korting HC (1982) Intraindividual Variations of 8-Methoxypsoralen Plasma Levels. *Arch Dermatol Res* 272:1-7
9. Korting HC, Schäfer-Korting M, Roser-Maass E, Mutschler E (1982) Determination of 8-Methoxypsoralen Levels in Plasma and Skin Suction Blister Fluid by a New Sensitive Fluorodensitometric Method. *Arch Dermatol Res* 272:9-20

10. Schäfer-Korting M, Korting HC, Hiemstra S, Mutschler E (1982) Does Cantharides Blister Fluid Provide Access to the Peripheral Compartment? *Eur J Clin Pharmacol* 23:327-330
11. Neubert U, Korting HC, Ruckdeschel G (1982) Susceptibility of *Neisseria gonorrhoeae* to Cefotaxime: in vitro Studies and Treatment Results. *Arch Dermatol Res* 274:321-326
12. Ruckdeschel G, Neubert U, Korting HC (1983) Distribution of Auxotypes and Correlation to Antibiotic Susceptibility of 169 Recent Clinical *Neisseria gonorrhoeae* Isolates from Munich. *Arch Dermatol Res* 275:388-392
13. Korting HC (1984) In vitro Susceptibility of Recent Isolates of *Neisseria gonorrhoeae* to Cephalosporins of Different Generations and Penicillin G: A Comparative Evaluation. *Dermatologica* 168:67-72
14. Korting HC (1984) Sind toxische Nebenwirkungen des Lidokains bei Verwendung als Lösungsmittelzusatz bei der Zephalosporin-Therapie der Gonorrhö zu erwarten? *Med Welt* 35:390-391
15. Korting HC, Schäfer-Korting M, Haag R, Mutschler E (1984) Plasma, cantharides blister fluid, and suction blister fluid levels of ceftizoxime after single intramuscular application for gonorrhoea. *Int J Clin Pharmacol Ther Toxicol* 22:218-220
16. Schäfer-Korting M, Korting HC, Dorn M, Mutschler E (1984) Ketoconazole concentrations in human skin blister fluid and plasma. *Int J Clin Pharmacol Ther Toxicol* 22:371-374
17. Korting HC (1984) Plasma and Skin Blister Fluid Levels of Cefotiam and Cefmenoxime after Single Intramuscular Application of 1 g in Gonorrhea. *Chemotherapy* 30:277-282
18. Korting HC, Neubert U (1984) Susceptibility of *Neisseria gonorrhoeae* to Ceftizoxime in vitro and in vivo. *Chemotherapy* 30:322-327
19. Korting HC, Behrendt H, Roth K-H, Neubert U (1984) Repeated Exposition to Subinhibitory Concentrations of Antibiotic in vitro Readily Decreases Susceptibility of *Neisseria gonorrhoeae* to Rifampicin, but not to New Cephalosporins and Penicillin G. *Chemotherapy* 30:366-372



20. Schäfer-Korting M, Korting HC, Mutschler E (1985) Human Plasma and Skin Blister Fluid Levels of Griseofulvin Following a Single Oral Dose. *Eur J Clin Pharmacol* 29:109-113
21. Korting HC, Abeck D, Neubert U (1985) Zur Bedeutung der Auxotypisierung von *Neisseria gonorrhoeae* für die Auswertung von Gonorrhoe-Therapiestudien. *Dermatologica* 171:175-179
22. Schäfer-Korting M, Korting HC, Mutschler E (1985) Human Plasma and Skin Blister Fluid Levels of Griseofulvin After its Repeated Administration. *Eur J Clin Pharmacol* 29:351-354
23. Korting HC, Neubert U (1985) Treatment of Gonorrhoea with Cefotiam: Activity in vitro and Clinical Results of a 1-Gram Single-Dose Regimen. *Dermatologica* 171:264-268
24. Korting HC, Abeck D, Neubert U (1986) The Susceptibility of *Neisseria gonorrhoeae* Strains to Different Cephalosporins and Penicillin G Depends on the Auxotype. *Chemotherapy* 32:247-254
25. Korting HC, Niederauer H, Ollert M (1986) Bactericidal Activity of Cefotiam and Ceftizoxime against *Neisseria gonorrhoeae* in an in vitro Model Simulating Plasma and Cantharidal Blister Fluid Levels after the Single Intramuscular Application of One Gram. *Chemotherapy* 32:260-269
26. Schäfer-Korting M, Korting HC, Maass L, Kiesel N, Grigoleit H-G, Mutschler E (1986) Cefodizime Penetration into Skin Suction Blister Fluid Following a Single Intravenous Dose. *Eur J Clin Pharmacol* 30:295-298
27. Korting HC, Weber K (1986) Ceftizoxime Induces Morphological Changes in *Neisseria gonorrhoeae* at Concentrations by far Lower than Minimal Inhibitory Concentration. *Eur J Sex Transm Dis* 3:157-162
28. Korting HC, Beckenkamp B (1986) Repeated Exposition of *Neisseria gonorrhoeae* to Subinhibitory Concentrations of Antibiotics in Liquid Medium Leads to a Fast Increase of its Resistance with Rifampicin, but not with Penicillin G, Cefotiam or Ceftizoxime. *Eur J Sex Transm Dis* 3:163-167

29. Korting HC, Abeck D (1986) Serum-resistant *Neisseria gonorrhoeae* Strains are Markedly Less Susceptible to Penicillin G and Cefotiam In Vitro, but not to the Newest Cephalosporins. *Eur J Sex Transm Dis* 3:169-172
30. Korting HC, Walther D, Riethmüller U, Meurer M (1986) Comparative in vitro Susceptibility of *Treponema pallidum* to Cefprozime, Ceftriaxone and Penicillin G. *Chemotherapy* 32:352-355
31. Korting HC, Schlaf-Maier U, Schäfer-Korting M (1986) Antimikrobielle Effekte des in vitro simulierten Ketoconazol-Kantharidinblasenflüssigkeitsspiegel-Profiles bei *Candida albicans*. *Mykosen* 29:297-305
32. Korting HC, Weber K (1986) Morphologische Effekte subinhibitorischer Penicillinkonzentrationen auf *Neisseria gonorrhoeae*. *Zeitschr Antimikrob Antineopl Chemother* 4:39-44
33. Korting HC, Abeck D, Neubert U (1986) Evaluation of Cefotetan in Uncomplicated Gonorrhea. *Dermatologica* 173:237-244
34. Korting, H.C, Abeck D, Neubert U (1986) In-vitro-Empfindlichkeit von *Neisseria gonorrhoeae* gegenüber Cefotetan und Ciprofloxacin – Abhängigkeit von Beta-lactamasebildung und Auxotyp. *Zeitschr Antimikrob Antineopl Chemother* 4:71-75
35. Korting HC, Maier W, Schäfer-Korting M (1986) In-vitro-Bakterizidie-Effekte von Ofloxacin bei *Streptococcus pyogenes*-Hautisolaten. *Zeitschr Antimikrob Antineopl Chemother* 4:103-107
36. Korting HC, Kober M, Müller M, Braun-Falco O (1987) Influence of Repeated Washings with Soap and Synthetic Detergents on pH and Resident Flora of the Skin of Forehead and Forearm. Results of a Cross-over Trial in Healthy Probitors. *Acta Derm Venereol* 67:41-47
37. Korting HC, Weber K (1987) Morphological Changes in *Neisseria gonorrhoeae* Induced by Various Subinhibitory Concentrations of Cefotiam. *Arzneimittelforschung/Drug Res* 37:135-138
38. Korting HC, Bau A, Baldauf P (1987) pH-Abhängigkeit des Wachstumsverhaltens von *Staphylococcus aureus* und *Propionibacterium acnes*. Implikationen

einer In-vitro-Studie für den optimalen pH-Wert von Hautwaschmitteln. *Ärztl Kosmetol* 17:41-53

39. Korting HC, Ollert M, Lukacs A, Schäfer-Korting M (1987) Can the Clinical Efficacy of Different Antibiotic Dosage Regimens in Gonorrhoea Be Predicted from the Gonocidal Effect of the Corresponding Plasma Level Profiles Simulated in vitro? *Acta Derm Venereol* 67:154-159
40. Korting HC, Abeck D, Neubert U, Blaufuß A (1987) Zur Bewertung des mikroskopischen Direktnachweises von Chlamydia trachomatis mit fluoreszenzmarkierten monoklonalen Antikörpern bei venerologisch-andrologischen Fragestellungen. *Akt Dermatol* 13:88-92
41. Schill W-B, Reiter F, Korting HC, Schweikert H-U (1987) Langzeittherapie der Oligozoospermie mit dem Aromatasehemmer Testolaktone. *Hautarzt* 38:395-399
42. Korting HC, Walther D, Riethmüller U, Meurer M (1987) Ceftriaxone Given Repeatedly Cures Manifest Syphilis in the Rabbit. *Chemotherapy* 33:376-380
43. Abeck D, Alexander F, Johnson AP, Korting HC, Taylor-Robinson D (1987) Prevalence of gonococci lacking the 2.6 Megadalton cryptic plasmid. *Lancet* 1:1440
44. Korting HC, Dorsch R (1987) Zur Korrelation von Biotyp und Antimykotikaisensibilität bei Candida albicans. *Mykosen* 30:512-519
45. Korting HC, Schäfer-Korting M, Maass L, Klesel N, Mutschler E (1987) Cefodizime in Serum and Skin Blister Fluid after Single Intravenous and Intramuscular Doses in Healthy Volunteers. *Antimicrob Agents Chemother* 31:1822- 1825
46. Korting HC, Abeck D, Schmoeckel C (1987) Vergleichende Bewertung des Herpes-Virus-Nachweises mittels fluoreszenzmarkierter monoklonaler Antikörper und elektronenmikroskopischer Negativkontrasttechnik bei dermatovenerologischen Erkrankungen. Ergebnisse einer Pilotstudie an 30 Patienten. *Hautarzt* 38:723-726
47. Korting HC, Käuffl M, Schäfer-Korting M (1987) Bakterizidie-Effekte des in vitro simulierten Cefotetan-Serumspiegelprofils bei Gonokokkenisolaten von geheil-

- ten und ungeheilten Gonorrhöpatienten. Zeitschr Antimikrob Antineopl Chemother 5:131-134
48. Hartinger A, Korting HC, Neubert U, Blaufuß H (1988) In-vitro-Wirksamkeit von Ofloxacin und Ciprofloxacin bei genitalen Chlamydia trachomatis-Isolaten gemessen an minimaler Hemmkonzentration (MHK) und minimaler bakterizider Konzentration (MBK). Zeitschr Hautkr 63:29-32
49. Korting HC, Lukacs A (1988) Zur Wirksamkeit von Ofloxacin gegen Neisseria gonorrhoeae. Imm Inf 16:3-5
50. Abeck D, Johnson AP, Korting HC (1988) Characterisation of penicillinase producing gonococci isolated in Munich, 1981-6. Genitourin Med 64:3-6
51. Korting HC, Hartinger A (1988) Minimale Hemmkonzentrationen (MHK) und minimale bakterizide Konzentrationen (MBK) von Tetrazyklin und Erythromycin bei 35 rezenten Münchener Chlamydia-trachomatis-Isolaten. Hautarzt 39:161-165
52. Korting HC, Ollert M, Niederauer H (1988) High Concentrations of Antibiotic Obtained for a Short Time Excel More Long-Standing Lower Levels in the Therapy of Gonorrhoea. Implications of an in vitro Model. Chemotherapy 34:142-148
53. Korting HC, Rohrßen U, Neubert U, Eckert F, Braun-Falco O (1988) Kulturell gesicherter Lupus vulgaris. Akt Dermatol 14:127-132
54. Abeck D, Johnson AP, Alexander FE, Korting HC, Taylor-Robinson D (1988) Plasmid content and protein I serovar of non-penicillinase-producing gonococci isolated in Munich Epidem Inf 100:345-349
55. Korting HC, Wild F, Schäfer-Korting M (1988) Bakterizider Effekt in vitro simulierter Serum- und Gewebespiegel von Cefodizim und Ofloxacin gegenüber Neisseria gonorrhoeae: Vorhersage auf der Basis statischer Untersuchungen. Zeitschr. Antimikrob Antineopl Chemother 6:29-35
56. Korting HC, Schill WB, Abeck D (1988) Erhöhte Nachweisrate von Ureaplasma urealyticum in menschlichem Sperma nach Verdünnung. Fertilität 4:125-127

57. Abeck D, Johnson AP, Alexander F, Korting HC, Ballard RC (1988) In vitro activity of eight antimicrobial agents against non-penicillinase-producing gonococci isolated in Munich. *Genitourin Med* 64:233-234
58. Korting HC, Abeck D, Johnson AB, Ballard RC, Taylor-Robinson D, Braun-Falco O (1988) Lectin Typing of *Haemophilus ducreyi*. *Eur J Clin Microbiol Infect Dis* 7:678-680
59. Korting HC, Maier W, Schäfer-Korting M (1988) In vitro-Bakterizidieeffekte von Ofloxacin bei *S. aureus*. *Zentralbl Bakt Hyg A* 269:387-394
60. Korting HC, Abeck D (1988) Lektin-Typisierung als leistungsfähiges epidemiologisches Markersystem für *Neisseria gonorrhoeae*-Infektionen. *Zentralbl Bakt Hyg A* 269:506-512
61. Korting HC, Ollert M, Georgii A, Fröschl M (1988) In Vitro Susceptibilities and Biotypes of *Candida albicans* Isolates from the Oral Cavities of Patients Infected with Human Immunodeficiency Virus. *J Clin Microbiol* 26:2626-2631
62. Korting HC, Lukacs A, Schäfer-Korting M, Mutschler E (1989) Bactericidal Effect of Cefodizime against  $\beta$ -Lactamase-producing *Neisseria gonorrhoeae* in vitro. A comparison of level profiles in serum and tissue after intramuscular and intravenous administration in man. *Arzneim-Forsch/Drug Res* 39:31-33
63. Korting HC, Lukacs A, Schäfer-Korting M, Heykants J, Behrendt H (1989) Skin Blister Fluid Levels of Ketoconazole During Repetitive Administration in Healthy Man. *Mycoses* 32:39-45
64. Abeck D, Johnson AP, Grimm W, Zaba R, Korting HC (1989) Plasmid content, Serotypes, and Antimicrobial Susceptibility of *Neisseria gonorrhoeae* Strains Isolated in Munich. *Eur J Epidemiol* 5:170-172
65. Korting HC, Seitz P, Kreller W (1989) Influence of Various Concentrations of Cefotiam and Ceftizoxime on the Phagocytosis of Gonococci by Polymorphonuclear Granulocytes. *Arzneimittelforschung/Drug Res* 39:428-431
66. Ballard RC, Abeck D, Korting HC, Dangor Y, Braun-Falco O (1989) Morphologische Varianten des durch *Haemophilus ducreyi* bedingten Genitalulcus. *Hautarzt* 40:443-447

67. Korting HC, Abeck D (1989) One-Shot Treatment of Uncomplicated Gonorrhoea with Third-Generation Cephalosporins with Differing Serum Half-Life. Results of a Controlled Trial with Ceftriaxone and Cefotaxime. *Chemotherapy* 35:441-448
68. Korting HC, Braun-Falco O (1989) Efficacy and tolerability of combined topical treatment of acne vulgaris with tretinoin and erythromycin in general practice. *Drugs Exper Clin Res* 15:447-451
69. Korting HC, Lukacs A (1989) Resistenzsteigerung vom Mehrschrittyp bei in vitro wiederholt subinhibitorischen Konzentrationen von Zweitgeneration-schinolonen ausgesetzten *Neisseria gonorrhoeae*-Isolaten. *Infection* 17, Suppl. 1:S6-S10
70. Korting HC, Rosenkranz S (1989) In vitro Susceptibility of Dermatophytes from Munich to Griseofulvin, Miconazole and Ketoconazole. *Mycoses* 33:136-139
71. Korting HC, Abeck D, Grimm W, Schiller Y (1990) Heutige In-vitro-Empfindlichkeit von Hautbakterien gegenüber unterschiedlichen Chemotherapeutika. Quantitative Ergebnisse des Mikrodilutionstests. *Akt Dermatol* 16:27-31
72. Warlich R, Korting HC, Schäfer-Korting M, Mutschler E (1990) Multiple-dose Pharmacokinetics of Ofloxacin in Serum, Saliva, and Skin Blister Fluid of Healthy Volunteers. *Antimicrob Agents Chemother* 34:78-81
73. Schäfer-Korting M, Korting HC, Lukacs A, Heykants J, Behrendt H (1990) Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. *J Am Acad Dermatol* 22:211-215
74. Abeck D, Korting HC, Grimm W, Zaba R (1990) Detection of a novel "cryptic" plasmid of about 7.8 MDal in a non-penicillinase-producing *Neisseria gonorrhoeae* isolate from Munich. *Eur J Epidemiol* 6:96-98
75. Korting HC, Abeck D, Zaba R (1990) Increase of the Relative Frequency of Penicillinase-producing *Neisseria gonorrhoeae* Strains to more than Five per Cent in Munich. *Zentralbl Bakt* 272:313-317
76. Abeck D, Johnson AP, Korting HC, Stolz W, Struck-Sauer E, Braun-Falco O (1990) Effect of iron limitation on protein composition and ultrastructure of *Haemophilus ducreyi*. *FEMS Microbiol Lett* 48:41-44

77. Korting HC, Zienicke H (1990) Dermatophytoses as Occupational Dermatoses in Industrialized Countries. *Mycoses* 33:86-89
78. Korting HC, Schäfer-Korting M, Kees F, Lukacs A, Grobecker H (1990) Skin tissue fluid levels of cefotiam in healthy man following oral cefotiam hexetil. *Eur J Clin Pharmacol* 39:33-36
79. Abeck D, Korting HC, Zaba R, Dangor Y, Fehler G, Ballard RC (1990) Soluble interleukin-2 receptors in serum and urine of patients with chancroid and their response to therapy. *Int J STD AIDS* 1:282-284
80. Behrendt H, Korting HC (1990) Experimental Evidence for Amide Hydrolysis of Indomethacin in Rabbit Skin. *Skin Pharmacol* 3:41-44
81. Korting HC, Hübner K, Greiner K, Hamm G, Braun-Falco O (1990) Differences in the Skin Surface pH and Bacterial Microflora Due to the Long-term Application of Synthetic Detergent Preparations of pH 55 and pH 70 Results of a Crossover Trial in Healthy Volunteers. *Acta Derm Venereol* 70:429-431
82. Lukacs A, Korting HC (1990) Nebenwirkungen eines neuen sauren Syndet-waschstücks. Art und Ausmaß bei regelmäßiger Anwendung unter Praxisbedingungen. *TW Dermatol* 20:416-423
83. Abeck D, Korting HC, Wagner R, Ballard R (1990) Hemagglutinating Properties of *Haemophilus ducreyi*. *Lett Appl Microbiol* 11:45-47
84. Korting HC, Zienicke H, Schäfer-Korting M, Braun-Falco O (1990) Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema but not in psoriasis vulgaris. *Eur J Clin Pharmacol* 39:349-351
85. Wolff H, Neubert U, Zebhauser M, Bezold G, Korting HC, Meurer M (1991) Chlamydia trachomatis induces an inflammatory response in the male genital tract and is associated with altered semen quality. *Fertil Steril* 55:1017-1019
86. Korting HC, Kerscher M, Vieluf D, Mehringer, L, Megele M, Braun-Falco O (1991) Commercial glucocorticoid formulations and skin dryness. Could it be due to the vehicle? *Acta Derm Venereol* 71:261-263
87. Korting HC, Megele M, Mehringer L, Vieluf D, Zienicke H, Hamm G, Braun-Falco O (1991) Influence of skin cleansing preparation acidity on skin surface properties. *Int J Cosmet Sci* 13:91-102

88. Peter RU, Korting HC (1991) Behandlung des seborrhoischen Ekzems mit Ketoconazol im Vergleich zu einer Wirkstoff-freien Pflegecreme. *Arzneimittelforschung/Drug Res* 41:852-854
89. Korting HC, Greiner K, Hübner K, Hamm G (1991) Changes in skin pH and resident flora by washing with synthetic detergent preparations at pH 55 and 85. *J Soc Cosmet Chem* 42:147-158
90. Lukacs A, Korting HC, Braun-Falco O, Stanzl K (1991) Efficacy of a deodorant and its components: Triethylcitrate and perfume. *J Soc Cosmet Chem* 42:159-166
91. Abeck D, Johnson AP, Hartinger A, Kollmann M, Korting HC, Ballard RC, Braun-Falco O (1991) Absence of extracellular enzyme activity and cytotoxicity in cell-free culture filtrates of *Haemophilus ducreyi*. *Microb Pathog* 10:405-410
92. Lukacs A, Korting HC, Ruckdeschel G, Ehret W (1991) Do cutaneous coryneforme bacteria produce short-chain fatty-acids in vitro? *Dermatologica* 182:32-34
93. Zienicke H, Korting HC, Lukacs A, Braun-Falco O (1991) Dermatophytosis in Children and Adolescents: Epidemiological, Clinical, and Microbiological Aspects Changing with Age. *J Dermatol* 18:438-446
94. Korting HC, Loferer S, Hamm N (1991) The detergent scrub method for quantitative determination of *Malassezia furfur* on chest and back skin: comparative evaluation of three different media. *Mycoses* 34:267-271
95. Schäfer-Korting M, Korting HC, Amann F, Peuser R, Lukacs A (1991) Influence of Albumin on Itraconazole and Ketoconazole Antifungal Activity: Results of a Dynamic In Vitro Study. *Antimicrob Agents Chemother* 35:2053-2056
96. Korting HC (1991) Letter to the Editor. *J Soc Cosmet Chem* 42:393-394
97. Korting HC, Vieluf D, Kerscher M (1992) 025 % Prednicarbate cream and the corresponding vehicle induce less skin atrophy than 01 % Betamethasone-17-valerate cream and 005 % Clobetasol-17-propionate cream. *Eur J Clin Pharmacol* 42:159-161



98. Abeck D, Korting HC, Kollmann M, Johnson AP, Ballard RC, Mensing H (1992) Lack of Immunoglobulin A1 Protease Production by *Haemophilus ducreyi*. *Zentralbl Bakt* 277:34-38
99. Abeck D, Korting HC, Braun-Falco O (1992) Folliculitis Decalvans Long-lasting Response to Combined Therapy with Fusidic Acid and Zinc. *Acta Derm Venereol* 72:143-145
100. Kerscher M, Korting HC (1992) Topical Glucocorticoids of the Non-fluorinated Double-ester Type Lack of Atrophogenicity in Normal Skin as Assessed by High-frequency Ultrasound. *Acta Derm Venereol* 72:214-216
101. Kerscher MJ, Korting HC (1992) Comparative Atrophogenicity Potential of Medium and Highly Potent Topical Glucocorticoids in Cream and Ointment according to Ultrasound Analysis. *Skin Pharmacol* 5:77-80
102. Korting HC, Lukacs A, Vogt N, Urban J, Ehret W, Ruckdeschel G (1992) Influence of the pH-Value on the Growth of *Staphylococcus epidermidis*, *Staphylococcus aureus* and *Propionibacterium acnes* in Continuous Culture. *Zentralbl Hyg Umweltmed* 193:78-90
103. Kerscher MJ, Korting HC (1992) Assessment of the atrophogenicity potential of chemically different topical glucocorticoids by high frequency ultra-sound. *Eur J Dermatol* 2:440-442
104. Korting HC, Abeck D (1992) The lectin type of *Candida albicans* - an epidemiological marker relevant to pathogenesis. *Mycoses* 35:89-94
105. Kollmann M, Korting HC (1992) Vergleichende Bewertung des Nachweises von Urethritis und Zervizitis ausgelöst durch *Neisseria gonorrhoeae* und *Chlamydia trachomatis* mittels DNA-Sonde und Kultur. *Akt Dermatol* 18:331-333
106. Korting HC, Lukacs A, Hamm D, Stanzl K, Braun-Falco O (1992) In-use tolerability of two new syndet bars with sodium cocoyl isethionate, disodium lauryl sulfosuccinate and wheat starch as major ingredients in differing relations: results of a cross-over trial. *Int J Cosmet Sci* 14: 277-282
107. Korting HC, Blecher P, Fröschl M, Braun-Falco O (1992) Quantitative assessment of the efficacy of oral ketoconazole for oral candidosis in HIV-infected patients. *Mycoses* 35:173-176

108. Korting HC, Parsch EM, Enders F, Przybilla B (1992) Allergic contact dermatitis to cocamidopropyl betaine in shampoo. *J Am Acad Dermatol* 27:1013-1015
109. Thomas PA, Schraut W, Korting HC, Braun-Falco O (1993) Papulo-necrotic tuberculids and erythema induratum of Bazin in a patient with a history of tuberculosis: role of specific T cells. *Eur J Dermatol* 3:97-101
110. Ollert MW, Thomas P, Korting HC, Schraut W, Braun-Falco O (1993) Erythema induratum of Bazin Evidence of T-Lymphocyte Hyperresponsiveness to Purified Protein Derivative of Tuberculin. *Arch Dermatol* 129:469-473
111. Korting HC, Zaba R, Ballard RC, Abeck D (1993) The suppressive effect of serum samples from patients with chancroid on human mononuclear cells correlates with the clinical picture and is interleukin-dependent. *Int J STD AIDS* 4:171-173
112. Korting HC, Schäfer-Korting M, Hart H, Schmid M (1993) Anti-inflammatory activity of hamamelis distillate applied topically to the skin Influence of vehicle and dose. *Eur J Clin Pharmacol* 44:315-318
113. Korting HC, Schmidt MH, Hartinger A, Maierhofer G, Stolz W, Braun-Falco O (1993) Evidence for the phagocytosis of intact oligolamellar liposomes by human keratinocytes in vitro and consecutive intracellular disintegration. *J Microencapsulation* 10:223-228
114. Zienicke H, Korting HC (1993) Clinical efficacy and tolerability of saperconazole for tinea of glabrous skin A Report on four cases. *Mycoses* 36:131-134
115. Korting HC, Haag R, Walter D, Riethmüller U, Meurer M (1993) Efficacy of Ceftiozime in the Treatment of Incubating Syphilis in Rabbits Chemotherapy 39:331-335
116. Korting HC, Kerscher M, Schäfer-Korting M, Berchtenbreiter U (1993) Influence of topical erythromycin preparations for acne vulgaris on skin surface pH. *Clin Invest* 71:644-648
117. Korting HC, Blecher P, Hamm G (1993) Dermatophytes on the feet of HIV-infected patients: frequency, species distribution, localization and antimicrobial susceptibility. *Mycoses* 36:271-374

118. Korting HC, Schäfer-Korting M, Zienicke H, Georgii A, Ollert MW (1993) Treatment of Tinea Unguium with Medium and High Doses of Ultramicrosized Griseofulvin Compared with That with Itraconazole. *Antimicrob Agents Chemother* 37:2064-2068
119. Schäfer-Korting M, Korting HC, Kerscher MJ, Lenhard S (1993) Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids. *Clin Pharmacol Ther* 54:448-456
120. Ollert W, Söhnchen R, Korting HC, Ollert U, Bräutigam S, Bräutigam W (1993) Mechanisms of Adherence of *Candida albicans* to Cultured Human Epidermal Keratinocytes. *Infect Immun* 61:4560-4568
121. Hart H, Kerscher M, Korting HC (1993) Summen-A-Mode-Verfahren bei Messungen der Hautdicke mit 20 MHz Sonographie. *Akt Dermatol* 19:351-354
122. Blecher P, Korting HC (1993) A new combined diagnostic approach to clinically and microscopically suspected onychomycosis unproven by culture. *Mycoses* 36:321-324
123. Zienicke H, Korting HC, Braun-Falco O, Effendy I, Hagedorn M, Küchmeister B, Meisel C (1993) Comparative efficacy and safety of bifonazole 1 % cream and the corresponding base preparation in the treatment of seborrhoeic dermatitis. *Mycoses* 36:325-331
124. Korting HC, Herzinger T, Hartinger A, Kerscher M, Angerpointner T, Maibach HI (1994) Discrimination of the irritancy potential of surfactants in vitro by two cytotoxicity assays using normal human keratinocytes, HaCaT cells and 3T3 mouse fibroblasts: correlation with in vivo data from a soap chamber assay. *J Dermatol Sci* 7:119-129
125. Hein R, Korting HC, Mehring T (1994) Differential Effect of Medium Potent Nonhalogenated Double-Ester-Type and Conventional Glucocorticoids on Proliferation and Chemotaxis of Fibroblasts in vitro. *Skin Pharmacol* 7:300-306
126. Korting HC, Schindler S, Hartinger A, Kerscher M, Angerpointner T, Maibach HI (1994) MTT-assay and neutral red release (NRR)-assay: relative role in the prediction of the irritancy potential of surfactants. *Life Sci* 55:533-540

127. Korting HC, Zienicke H, Braun-Falco O, Bork K, Milbradt R, Nolting S, Schöpf E, Tronnier H (1994) Modern Topical Glucocorticoids and Anti-infectives for Superinfected Atopic Eczema: Do Prednicarbate and Didecylidimethylammoniumchloride Form a Rational Combination? *Infection* 22:390-394
128. Schäfer-Korting M, Korting HC, Ponce-Pöschl E (1994) Liposomal tretinoin for uncomplicated acne vulgaris. *Clin Investig* 72:1086-1091
129. Lukacs A, Korting HC, Lindner A (1994) Successful treatment of griseofulvin-resistant tinea capitis in infants. *Mycoses* 37:451-453
130. Korting HC, Stolz W, Schmid M-H, Maierhofer G (1995) Interaction of liposomes with human epidermis reconstructed in vitro. *Br J Dermatol* 132:571-579
131. Korting HC, Ponce-Pöschl E, Klövekorn W, Schmötzer G, Arens-Corell M, Braun-Falco O (1995) The influence of the regular use of a soap or an acidic syndet bar on pre-acne. *Infection* 23:89-94
132. Kerscher MJ, Hart H, Korting HC, Stalleicken D (1995) In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new. *Int J Clin Pharmacol Ther* 33:187-189
133. Korting HC, Ollert M, Abeck D, and the German Collaborative Dermatophyte Drug Susceptibility Study Group (1995) Results of German Multicenter Study of Antimicrobial Susceptibility of *Trichophyton rubrum* and *Trichophyton mentagrophytes* Strains Causing Tinea unguium. *Antimicrob Agents Chemother* 39:1206-1208
134. Korting HC, Hülsebus E, Kerscher M, Greber R, Schäfer-Korting M (1995) Discrimination of the toxic potential of chemically differing topical glucocorticoids using a neutral red release assay with human keratinocytes and fibroblasts. *Br J Dermatol* 133:54-59
135. Ollert W, Wende C, Görlich M, McMullan-Vogel CG, Borg-von-Zepelin M, Vogel CW, Korting HC (1995) Increased Expression of *Candida albicans* Secretory Protease, a Virulence Factor, in Isolates from Human Immunodeficiency Virus-Positive Patients. *J Clin Microbiol* 33:2543-2549

136. Korting HC, Schäfer-Korting M, Klövekorn W, Klövekorn D, Martin L, Laux P (1995) Comparative efficacy of Hamamelis distillate and hydrocortisone cream in atopic eczema. *Eur J Clin Pharmacol* 48:461-465
137. Schäfer-Korting M, Korting HC, Rittler W, Obermüller W (1995) Influence of Serum Protein Binding on the in vitro Activity of Antifungal Agents. *Infection* 23:292-297
138. Blecher P, Korting HC (1995) Tolerance of different toilet paper preparations: toxicological and allergological aspects. *Dermatology* 191:299-304
139. Lukacs A, Korting HC, Lemke O, Ruckdeschel G, Ehret W, Braun-Falco O (1995) The Influence of the pH-Value on the Growth of *Brevibacterium epidermidis* in Continuous Culture. *Acta Derm Venereol* 75:280-282
140. Schaller M, Korting HC, Schmid M-H (1996) Interaction of cultured human keratinocytes with liposomes encapsulating silver sulfadiazine: proof of the uptake of intact vesicles. *Br J Dermatol* 134:445-450
141. Kerscher MJ, Korting HC, Mehringer L, Mätzig R (1996) 0,05 % clobetasol 17-propionate cream and ointment but not the corresponding 01 % triamcinolone acetonide preparations increase skin surface roughness: A possible dissociation of unwanted epidermal and dermal effects. *Skin Pharmacol* 9:120-123
142. Schaller M, Wurm R, Korting HC (1997) Direct evidence for uptake of intact liposomes encapsulating silver sulfadiazine by cultured human keratinocytes based on combined transmission electron microscopy and X-ray microanalysis. *Antimicrob Agents Chemother* 41:717-719
143. Schaller M, Steinle R, Korting HC (1997) Light and electron microscopic findings in human epidermis reconstructed in vitro upon topical application of liposomal tretinoin. *Acta Derm Venereol* 77:122-126
144. Gottlöber P, Kerscher MJ, Korting HC, Peter RU (1997) Sonographic determination of cutaneous and subcutaneous fibrosis after accidental exposure to ionising radiation in the course of the chernobyl nuclear power plant accident. *Ultrasound. Med Biol* 23:9-15

145. Abeck D, Freinkel AL, Korting HC, Szeimies R-M, Ballard RC (1997) Immunohistochemical investigations of genital ulcers caused by *Haemophilus ducreyi*. *Int J STD AIDS* 8:585-588
146. Gysler A, Lange K, Korting HC, Schäfer-Korting M (1997) Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts. *Pharm Res* 14:793-797
147. Korting HC, Klövekorn W, Klövekorn G and the Ecosome Collaborative Study Group (1997) Comparative efficacy and tolerability of econazole liposomal gel 1 %, branded econazole conventional cream 1 % and generic clotrimazole cream 1 % in tinea pedis. *Clin Drug Invest* 14:286-293
148. Lange K, Gysler A, Bader M, Kleuser B, Korting HC, Schäfer-Korting M (1997) Prednicarbate versus conventional topical glucocorticoids: Pharmacodynamic characterization in vitro. *Pharm Res* 14:1744-1749
149. Hoegl L, Schöniat G, Ollert M, Korting HC (1998) *Candida* sake: a relevant species in the context of HIV-associated oropharyngeal candidosis? *J Mol Med* 76:70-73
150. Niewerth M, Splanemann V, Korting HC, Ring J, Abeck D (1998) Antimicrobial susceptibility testing of dermatophytes - comparison of the agar microdilution and broth microdilution test. *Chemotherapy* 44:31-35
151. Kim DS, Korting HC, Schäfer-Korting M (1998) Effect of growth factors on the proliferation of human keratinocytes and fibroblasts in vitro. *Pharmazie* 53:51-57
152. Korting HC, Patzak U, Schaller M, Maibach HI (1998) A Model of Human Cutaneous Candidosis Based on Reconstructed Human Epidermis for the Light and Electron Microscopic Study of Pathogenesis and Treatment. *J Infect* 36:259-267
153. Korting HC, Neubert U, Abeck D (1998) Current antimicrobial susceptibility of cutaneous bacteria to first line antibiotics. *Int J Antimicrob Agents* 10:165-168
154. Schaller M, Schäfer W, Korting HC, Hube B (1998) Differential expression of secreted aspartyl proteinases in a model of human oral candidosis and in patient samples from the oral cavity. *Mol Microbiol* 29:605-615

155. Abeck D, Korting HC, Mempel M (1998) Prospective analysis of STD related genital ulcers from Hamburg. *Int J STD AIDS*, Letter:380
156. Hoegl L, Thoma-Greber E, Röcken M, Korting HC (1998) HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: a 2-year study. *Mycoses* 41:321-325
157. Schaller M, Hube B, Ollert MW, Schäfer W, Borg-von Zepelin M, Thoma-Greber E, Korting HC (1999) *In Vivo* Expression and Localization of *Candida albicans* Secreted Aspartyl Proteinases during Oral Candidiasis in HIV-infected patients. *J Invest Dermatol* 112:383-386
158. Schaller M, Preidel H, Januschke E, Korting HC (1999) Light and Electron Microscopic Findings in a Model of Human Cutaneous Candidosis Based on Reconstructed Human Epidermis upon the Topical Application of Different Econazole Formulations. *J Drug Target* 6:361-372
159. Grundmann-Kollmann M, Korting HC, Behrens S, Kaskel P, Leiter U, Krähn G, Kerscher M, Peter RU (1999) Mycophenolate mofetil: A new therapeutic option in the treatment of blistering autoimmune diseases. *J Am Acad Dermatol* 40:957-960
160. Korting HC, Schaller M, Eder G, Hamm G, Böhmer U, Hube B (1999) Effects of the Human Immunodeficiency Virus (HIV) Proteinase Inhibitors Sacquinavir and Indinavir on *In Vitro* Activities of Secreted Aspartyl Proteinases of *Candida albicans* Isolates from HIV-Infected Patients. *Antimicrob Agents Chemother* 43:2038-2042
161. Schaller M, Korting HC, Schäfer W, Bastert J, Chen WC, Hube B (1999) Secreted aspartic proteinase (Sap) activity contributes to tissue damage in a model of human oral candidosis. *Mol Microbiol* 34:169-180
162. Gysler A, Kleuser B, Sippl W, Lange K, Korting HC, Höltje H-D, Schäfer-Korting M (1999) Skin Penetration and Metabolism of Topical Gluco-corticoids in Reconstructed Epidermis and in Excised Human Skin. *Pharmaceutical Res* 10:1386-1391
163. Bastert J, Korting HC, Traenkle P, Schmalreck AF (1999) Identification of dermatophytes by Fourier transform infrared spectroscopy (FT-IR). *Mycoses* 42:525-528

164. Lange K, Kleuser B, Gysler A, Bader M, Maia C, Scheidereit C, Korting HC, Schäfer-Korting M (2000) Cutaneous Inflammation and Proliferation in vitro: Differential Effects and Mode of Action of Topical Glucocorticoids. *Skin Pharmacol Appl Skin Physiol* 13:93-103
165. Schaller M, Schackert C, Korting HC, Januschke E, Hube B (2000) Invasion of *Candida albicans* Correlates with Expression of Secreted Aspartic Proteinases during Experimental Infection of Human Epidermis. *J Invest Dermatol* 114: 712-717
166. Heinz WJ, Kurzai O, Brakhage AA, Fonzi WA, Korting HC, Frosch M, Mühlischlegel FA (2000) Molecular responses to changes in the environmental pH are conserved between the fungal pathogens *Candida dubliniensis* and *Candida albicans*. *Int J Med Microbiol* 290:231-238
167. Kurzai O, Korting HC, Harmsen D, Bautsch W, Molitor M, Frosch M, Mühlischlegel FA (2000) Molecular and phenotypic identification of the yeast pathogen *Candida dubliniensis*. *J Mol Med* 78:521-529
168. Bonowitz A, Schaller M, Laude J, Reimer K, Korting HC (2001) Comparative therapeutic and toxic effects of different povidone iodine (PVP-I) formulations in a model of oral candidiasis based on in vitro reconstituted epithelium. *J Drug Targ* 9:75-83
169. Kick G, Korting HC (2001) The definition of *Trichophyton rubrum* syndrome. *Mycoses* 44:167-171
170. Schaller M, Januschke E, Schackert C, Woerle B, Korting HC (2001) Different isoforms of secreted aspartyl proteinases (Sap) are expressed by *Candida albicans* during oral and cutaneous candidiasis in vivo. *J Med Microbiol* 50:743-747
171. Korting HC, Tietz H-J, Bräutigam M, Mayser P, Ragatz G, Paul C (2001) One week terbinafine 5 % cream (Lamisil®) once daily is effective in the treatment of interdigital tinea pedis: a vehicle controlled study. *Med Mycol* 39:335-340
172. Manggau M, Kim DS, Ruwisch L, Vogler R, Korting HC, Schäfer-Korting M, Kleuser B (2001) 1,25-Dihydroxyvitamin D<sub>3</sub> protects human keratinocytes from apoptosis by the formation of sphingosin-1-phosphate. *J Invest Dermatol* 117:1241-1249



173. Bader O, Schaller M, Klein S, Kukula J, Haack K, Mühlischlegel F, Korting HC, Hube B (2001) The KEX2 gene of *Candida glabrata* is required for cell surface integrity. *Mol Microbiol* 41:1431-1444
174. Korting HC, Unholzer A, Schäfer-Korting M, Tausch I, Gasmüller J, Nietsch KH (2001) Differential skin thinning potential of equipotent medium-strength glucocorticoids. *Skin Pharmacol Appl Skin Physiol* 15:85-91
175. Kretschmar M, Felk A, Staib P, Schaller M, Heß D, Callapina M, Morschhäuser J, Schäfer W, Korting HC, Hof H, Hube B, Nichterlein T (2002) Individual acid aspartic proteinases (Saps) 1-6 of *Candida albicans* are not essential for invasion and colonization of the gastrointestinal tract in mice. *Microb Pathog* 32:61-70
176. Unholzer A, Schinzel S, Nietsch K-H, Jung GE, Korting HC (2002) Ciclopiroxolamine Cream 1 % in the treatment of seborrhoeic dermatitis A double-blind, parallel-group comparison with ketoconazole and vehicle in a confirmatory trial. *Clin Drug Invest* 22:167-172
177. Schaller M, Mailhammer R, Grassl G, Sander CA, Hube B, Korting HC (2002) Infection of human oral epithelia with *Candida* species induces cytokine expression correlated to the degree of virulence. *J Invest Dermatol* 118:652-657
178. Felk A, Kretschmar M, Albrecht A, Schaller M, Beinhauer S, Nichterlein T, Sanglard D, Korting HC, Schäfer W, Hube B (2002) *Candida albicans* hyphal formation and the expression of the Efg1-regulated proteinases Sap4-6 are required for the invasion of parenchymal organs. *Infect Immun* 70:3689-3700
179. Schmid-Wendtner M, Partsch K, Korting HC, Volkenandt M (2002) Improved differentiation of benign and malignant lymphadenopathia in patients with cutaneous melanoma by contrast-enhanced color doppler-sonography. *Arch Dermatol* 138:491-497
180. Mempel M, Schnopp C, Hojka M, Fesq H, Weidinger S, Schaller M, Korting HC, Ring J, Abeck D (2002) Invasion of human keratinocytes by *Staphylococcus aureus* and intracellular bacterial persistence represent haemolysin-independent virulence mechanisms that are followed by features of necrotic and apoptotic keratinocyte cell death. *Br J Dermatol* 146:943-951

181. Schaller M, Mailhammer R, Korting HC (2002) Cytokine expression induced by *Candida albicans* in a model of cutaneous candidosis based on reconstructed human epidermis. *J Med Microbiol* 51:672-676
182. Santos Maia C, Mehnert W, Schaller M, Korting HC, Gysler A, Haberland A, Schäfer-Korting M (2002) Drug targeting by solid lipid nanoparticles for dermal use: Improvement of the benefit/risk ratio of topical glucocorticoids. *J Drug Targ* 10:489-495
183. Unholzer A, Varigos G, Nicholls D, Schinzel S, Nietsch K-H, Ulbricht H, Korting HC (2002) Ciclopiroxolamine cream for treating seborrheic dermatitis: a double-blind parallel group comparison. *Infection* 30:373-377
184. Thoma-Greber E, Zenker S, Röcken M, Wolff H, Korting HC (2003) Surgical treatment of tinea capitis in childhood. *Mycoses* 46:351-354
185. Schaller M, Kmjaic N, Niewerth M, Hamm G, Hube B, Korting HC (2003) Effect of antimycotic agents on the activity of aspartyl proteinases secreted by *Candida albicans*. *J Med Microbiol* 52:247-249
186. Schaller M, Bein M, Korting HC, Baur S, Hamm G, Monod M, Beinhauer S, Hube B (2003) The Secreted Aspartyl Proteinases Sap1 and Sap2 Cause Tissue Damage in an In Vitro Model of Vaginal Candidiasis Based on Reconstituted Human Vaginal Epithelium. *Infect Immun* 71:3227-3234
187. Niewerth M, Kunze D, Seibold M, Schaller M, Korting HC, Hube B (2003) Ciclopirox Olamine Treatment Affects the Expression Pattern of *Candida albicans* Genes Encoding Virulence Factors, Iron Metabolism Proteins, and Drug Resistance Factors. *Antimicrob Agents Chemother* 47:1805-1817
188. Korting HC, Hube B, Oberbauer S, Januschke E, Hamm G, Albrecht A, Borelli C, Schaller M (2003) Reduced expression of the hyphal-independent *Candida albicans* proteinase genes SAP1 and SAP3 in the *efg1* mutant is associated with attenuated virulence during infection of oral epithelium. *J Med Microbiol* 52:1-10
189. Susilo R, Korting HC, Strauss UP, and The Sertaconazole Study Group (2003) Dermatomycoses of the Glabrous Skin. A Double-Blind, Randomised, Comparative Trial of Sertaconazole 2% Cream Once Daily Versus Vehicle. *Clin Drug Invest* 23:387-394

190. Spika I, Hammer S, Kleuser B, Korting HC, Schäfer-Korting M (2003) Transcriptional Activity of Potent Glucocorticoids: Relevance of Glucocorticoid Receptor Isoforms and Drug Metabolites. *Skin Pharmacol Appl Skin Physiol* 16:143-150
191. Schaller M, Laude J, Bodewaldt H, Hamm G, Korting HC (2004) Toxicity and Antimicrobial Activity of a Hydrocolloid Dressing Containing Silver Particles in an ex vivo Model of Cutaneous Infection. *Skin Pharmacol Physiol* 17:31-36
192. Sivaramakrishnan R, Nakamura C, Mehnert W, Korting HC, Kramer KD, Schäfer-Korting M (2004) Glucocorticoid entrapment into lipid carriers – characterisation by paelectric spectroscopy and influence on dermal uptake. *J Control Release* 97:493-502
193. Roeder A, Kirschning CJ, Schaller M, Weindl G, Wagner H, Korting HC, Rupec R (2004) Induction of Nuclear Factor- $\kappa$ B and c-Jun/Activator Protein-1 via Toll-Like Receptor 2 in Macrophages by Antimycotic-Treated *Candida albicans*. *J Infect Dis* 190:1318-1326
194. Schreiber S, Mahmoud A, Vuia A, Rübhelke MK, Schmidt E, Schaller M, Kandárová H, Haberland A, Schäfer UF, Bock U, Korting HC, Liebsch M, Schäfer-Korting M (2005) Reconstructed epidermis versus human and animal skin in skin absorption studies. *Toxicol In Vitro* 19:813-822
195. Sigle HC, Thewes S, Niewerth M, Korting HC, Schäfer-Korting M, Hube B (2005) Oxygen accessibility and iron levels are critical factors for the antifungal action of ciclopirox against *Candida albicans*. *J Antimicrob Chemother* 55:663-673
196. Schaller M, Korting HC, Borelli C, Hamm G, Hube B (2005) *Candida albicans*-Secreted Aspartic Proteinases Modify the Epithelial Cytokine Response in an In Vitro Model of Vaginal Candidiasis. *Infect Immun* 73:2758-2765
197. Korting HC, Maslen K, Groß G, Willers C (2005) Vergleich der Wirksamkeit verschiedener topischer Glukokortikoidcremes und -salben im Vaso-konstriktionstest: Überlegenheit von Hydrocortisonbutyrat gegenüber Hydrocortison. *JDDG* 3:348-353

198. Susilo R, Korting HC, Strauss UP, Menke G, Schuster O, Menke A (2005) Rate and Extent of Percutaneous Absorption of Sertaconazole Nitrate after Topical Administration. *Arzneim-Forsch/Drug Res* 55:338-342
199. Borelli C, Kunte C, Weisenseel P, Thoma-Greber E, Korting HC, Konz B (2005) Deep Subcutaneous Application of Poly-L-Lactic Acid as Filler for Facial Lipotrophy in HIV-Infected Patients. *Skin Pharmacol Physiol* 18:273-278
200. Haberland A, Schreiber S, Santos Maia C, Rübhelke MK, Schaller M, Korting HC, Kleuser B, Schimke I, Schäfer-Korting M (2006) The impact of skin viability on drug metabolism and permeation – BSA toxicity on primary keratinocytes. *Toxicol In Vitro* 20:347-354
201. Lombardi Borgia S, Regehly M, Sivaramakrishnan R, Mehnert W, Korting HC, Danker K, Röder B, Kramer KD, Schäfer-Korting M (2006) Lipid nanoparticles for skin penetration enhancement – correlation to drug localization within the particle matrix as determined by fluorescence and piezoelectric spectroscopy. *J Control Release* (article in press)
202. Sigle HC, Schäfer-Korting M, Korting HC, Hube B, Niewerth M (2006) *In vitro* investigations on the mode of action of the hydroxypyridone antimycotic rilopirox and piroctone on *Candida albicans*. *Mycoses* 49: 159-168
203. Korting HC, Burkard T, Unkauf M, Schaffrik M (2006) Fußpilzerkrankung: Therapie mit Terbinafin-Crème. *Dtsch Apoth Ztg* 146:75-78
204. Susilo R, Korting HC, Greb W, Strauss UP (2006) Nail Penetration of Sertaconazole with a Sertaconazole-Containing Nail Patch Formulation. *Am J Clin Dermatol* 7:259-262
205. Ortonne JP, Korting HC, Viguié-Vallanet C, Larnier C, Savalun E (2006) Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athlete's foot): a randomized, double-blind, placebo-controlled study. *J EADV* 20:1307-1313
206. Placzek M, van den Heuvel ME, Flaig MJ, Korting HC (2006) Perniosis-like tinea corporis caused by *Trichophyton verrucosum* in cold-exposed individuals. *Mycoses* 49:476-479

207. Schäfer-Korting M, Bock U, Gamer A et al. (2006) Reconstructed human epidermis for skin absorption testing: results of the German prevalidation study. ATLA 34:283-294

## Case reports

1. Korting HC, Lesch R (1978) Acute cholangitis after allopurinol treatment. *Lancet* 1:275-276
2. Korting HC, Rohrbach R, Jontofsohn, R (1978) Endemische Nephropathie (Balkannephritis). *Med Welt* 29:1433-1437
3. Korting HC, Abegg F, Mittermayer C (1978) Pseudoaneurysm of the Heart Complicating Myocardial Infarction. *Path Res Pract* 163:76-86
4. Korting HC, Tröscher W (1978) Arthritis und Erythema nodosum als typische Manifestationen einer *Yersinia-enterocolitica*-Infektion. *Med Welt* 29:1754-1758
5. Korting HC, Rohrbach R (1978) Dextran-induzierte Pseudolungenembolie - Dextran-Unverträglichkeit mit tödlichem Ausgang. *Inn Med* 5:352-355
6. Korting HC (1978) Diäthylpentenamid-induziertes Hautulkus. *Akt Dermatol* 4:249-252
7. Korting HC, Pfeiffer B, Schranz W (1979) Penicillin-G-induzierte Leukopenie bei Endocarditis lenta. *Z Kardiologie* 68:177-179
8. Korting HC, Schranz W (1979) Knochenmarksdepression mit peripherer Panzytopenie unter der Gabe einer Ampicillin/Oxacillin-Kombination. *Z Kardiologie* 68:772-775
9. Korting HC, Kolz R, Schmoeckel C, Balda B-R (1981) Amiodaronepigmentierung Eine seltene, aber typische Medikamentennebenwirkung. *Hautarzt* 32:301-305
10. Wolff HH, Korting HC, Vigl E (1981) Multiple Glomustumoren. *Hautarzt* 32:354-358
11. Korting HC, Konz B (1982) Koinzidenz multipler Zylindrome mit Trichoepitheliomen (Brooke-Spiegler-Syndrom). *Hautarzt* 33:34-36
12. Korting HC, Neubert U (1982) Bakterielle Tripel-Infektion der Cervix uteri im Rahmen einer benignen Gonokokken-Sepsis. *Fortschr Med* 100:639-695

13. Braun-Falco O, Balda B-R, Korting HC, Blick U, Loeschke K, Begemann F (1982) Arznei-induziertes tödliches Lyell-Syndrom unter kombinierter Benoxaprofen-Aurothioglukose-Therapie. Münch Med Wochenschr 124:757-759
14. Korting HC, Luderschmidt C, Neubert U (1983) Übertragung eines  $\beta$ -Laktamase-bildenden Gonokokkenstammes zwischen zwei Deutschen in Hamburg. Med Welt 34:666-667
15. Korting HC, Neubert U, Braun-Falco O (1983) Erregernachweis im Blut bei disseminierter Gonokokkeninfektion Hautarzt 34:403-406
16. Korting HC, Abeck D, Neubert U (1983) Cultural Proof of Neisseria gonorrhoeae in Synovial Fluid in Disseminated Gonococcal Infection. Dermatologica 167:204-207
17. Korting HC, Blick U, Hamperl W-D (1983) Coincidence of Primary Malignant Melanoma of Skin and Eye Report of a Case without B-K Mole Syndrome but with a Further Malignancy. Dermatologica 167:317-321
18. Korting HC, Neubert U (1984) Sexuell übertragene Giardia lamblia-Infektionen bei einem Homosexuellen. Akt Dermatol
19. Korting HC, Neubert U, Abeck D, Jordan R, Luderschmidt C (1985) Gonoblenorrhoea adutorum (Gonococcal Conjunctivitis) - A "Disappearing Disease" Which Does Not Disappear. Dermatologica 170:17-21
20. Korting HC, Weinrauch L (1985) Kutane Leishmaniase. Kultureller Erregernachweis bei einem deutschen Ehepaar und Therapie mit Ketoconazol. Med Welt 36:762-764
21. Neubert U, Korting HC, Luderschmidt C, Braun-Falco O (1985) Preputial Abscesses Caused by Beta-Lactamase-Producing Gonococci. Cutis 31:161 - 163
22. Korting HC, Strasser S, Konz B (1988) Multiple BCG-Ulzera nach subkutaner Impfstoffapplikation im Rahmen der Immunochemotherapie des malignen Melanoms. Hautarzt 39:170-173

23. Korting HC, Abeck D, Johnson AP (1988) Presence of Two Strains of *Neisseria gonorrhoeae* in Both the Cervix and Pharynx of a Patient with Disseminated Infection Caused by a Single Strain. *Dermatologica* 176:212-218
24. Besenhard H-M, Korting HC, Stolz W, Braun-Falco O (1988) Disseminierte superfizielle aktinische Porokeratose (DSAP) mit Morbus Bowen. *Hautarzt* 39:286-290
25. Pauletzki J, Mannes GA, Sauerbruch T, Korting HC (1988) Fieber mit vesikulösem Exanthem und Pharyngitis bei einem 20jährigen Patienten (*Mycoplasma pneumoniae*-assoziiertes Stevens-Johnson-Syndrom). *Internist* 29:356-360
26. Braun-Falco O, Korting HC, Zienicke H, Klövekorn W (1988) Eruptive Histiozytome und Xanthoma disseminatum als Manifestationsformen derselben Erkrankung? *Hautarzt* 39:652-657
27. Korting HC, Abeck D, Neubert U, Johnson AP, Fröschl M, Braun-Falco O (1989) Diagnose und Therapie des Ulcus molle Kasuistik und Literaturübersicht. *Hautarzt* 40:418-422
28. Zienicke H, Korting HC (1989) Innerfamiliäre Übertragung von *Trichophyton verrucosum* auf ein Neugeborenes. *Mycoses* 32:411-415
29. Grimm W, Korting HC, Stolz W (1989) Disseminierter Zoster bei chronischer lymphatischer Leukämie. *Hautarzt* 40:582-585
30. Abeck D, Korting HC, Ring J (1990) Kontakturtikaria mit Übergang in eine Protein-Kontaktdermatitis bei einem Koch mit atopischer Diathese. *Dermatosen Ber Umw* 38:24-26
31. Vieluf D, Korting HC, Braun-Falco O, Walther J-U (1990) Dubowitz Syndrome: Atopic Dermatitis, Low Birth Weight Dwarfism and Facial Dysmorphism. *Dermatologica* 180:247-249
32. Schrällhammer K, Przybilla B, Söhnchen R, Korting HC, Ring J (1990) Artefizielle Pricktest-Reaktionen gegen Weizenmehl zur Vortäuschung einer Berufserkrankung. *Allergologie* 13:270-272



33. Abeck D, Neubert U, Hartinger A, Korting HC (1990) Beitrag zur gegenwärtigen Resistenzsituation von *Haemophilus ducreyi* in Deutschland: Ciprofloxacin-Empfindlichkeit bei Cotrimoxazol-Resistenz. *Akt Dermatol* 16:217-220
34. Behrendt H, Korting HC, Ring J (1990) Disseminierte Tuberculosis cutis colli-quativa infolge hämatogener Streuung von *Mycobacterium tuberculosis*. *Zeitschr Hautkr* 65:1036-1038
35. Korting HC, Vieluf D (1991) Erythema multiforme and dermatitis seborrhoides infantum as concomitant id-reactions to widespread candidosis in a suckling. *Mycoses* 34:415-417
36. Korting HC, Zienicke H (1991) Cultural evidence for a bullous type of tinea pedis. *Mycoses* 34:419-422  
Deutsche Fassung: Korting HC, Zienicke H (1991) Kulturelle Sicherung einer bullösen Form der Tinea pedis. *Mycoses* 34 (Suppl):103-106
37. Abeck D, Eckert F, Korting HC (1992) Atypical Presentation of Co-existent *Haemophilus ducreyi* and *Treponema pallidum* Infection in an HIV-positive Male. *Acta Derm Venereol* 72:37-38
38. Nachbar F, Korting HC, Vogl T (1993) Erythema multiforme-like Eruption in Association with Severe Headache following Pyritinol. *Dermatology* 187:42-46
39. Zienicke H, Korting HC (1993) Clinical efficacy and tolerability of saperconazole for tinea of glabrous skin A report on four cases. *Mycoses* 36:131-134
40. Nachbar F, Korting HC, Schirren CG (1994) Bullöse Dermatoze und Hautangrän durch paravasale Überinfusion. *Dermatosen Ber Umw* 42:27-30
41. Nachbar F, Korting HC, Hoffmann RM, Kollmann M, Meurer M (1994) Unusual Coexistence of Systemic Lupus erythematosus and Primary Biliary Cirrhosis. *Dermatology* 188:313-317
42. Thoma-Greber E, Korting HC, Regner J, Goebel F-D (1994) Fluconazole-resistant oral candidosis in a repeatedly treated female AIDS patient. *Mycoses* 37:35-38

43. Wlotzke U, Stolz W, Hohenleutner U, Riethmüller P, Korting HC, Landthaler M (1994) Interdisziplinäre Aspekte der Notalgia paraesthetica. Dtsch Med Wochenschr 119:1307-1311
44. Thomas P, Korting HC, Strassl W, Ruzicka T (1994) Microsporum canis infection in a five-year-old boy: transmission from the contaminated interior of a recently acquired second-hand car. Mycoses 37:141-142
45. Wolff H, Schaller M, Panhans A, Korting HC, Meurer M (1994) Das Immotile-Zilien-Syndrom. Hautarzt 45:611-614
46. Szeimies R-M, Stolz W, Wlotzke U, Korting HC, Landthaler M (1994) Successful treatment of hydroxyethyl starch-induced pruritus with topical capsaicin. Br J Dermatol 131:380-382
47. Hörmann HP, Korting HC (1994) Akute allergische Kontaktdermatitis auf Arnika-Tinktur. Derm Beruf Umwelt 42:246-249
48. Schaller M, Korting HC (1995) Erfolgreiche Therapie einer ausgedehnten Larva migrans mit dem neu eingeführten Breitspektrumanthelminthikum Albendazol. Derm Beruf Umwelt 43:26-28
49. Schaller M, Korting HC (1995) Allergic airborne contact dermatitis from essential oils used in aromatherapy. Clin Exp Dermatol 20:143-145
50. Schaller M, Korting HC (1995) Pseudoerythroprosopalgie. Akt Dermatol 21:48-50
51. Hörmann HP, Korting HC (1995) Allergic acute contact dermatitis due to Arnica tincture self-medication. Phytomedicine 4:315-317
52. Schlüpen EM, Korting HC, Nachbar F, Volkenandt M (1995) Molecular evidence for the existence of disseminated zoster as a distinct entity in an immunosuppressed renal transplant patient. J Mol Med 73:525-528
53. Gottlöber P, Krähn G, Schirren CG, Korting HC, Stock W, Peter R-U (1996) Behandlung der kutanen Strahlenfibrose mit Pentoxifyllin und Vitamin E. Strahlenther Onkol 172:34-38
54. Schaller M, Korting HC, Wolff H, Schirren CG, Burgdorf W (1996) Multiple keratoacanthomas, giant keratoacanthomas and keratoacanthoma centrifugum

- marginatum: Development in a single patient and treatment with oral isotretinoin. *Acta Derm Venereol* 76:40-42
55. Schaller M, Korting HC, Kollmann M, Kind P (1996) The hyperkeratotic variant of porokeratosis Mibelli is a distinct entity: clinical and ultrastructural evidence. *Dermatology* 192:255-258
56. Gottlöber P, Krähn G, Korting HC, Peter RU (1996) Diagnosestellung mittels Dermatoskopie und 20 MHz-Sonographie: Malignes Melanom versus Basaliom. *Z Hautkrankh* 12:897-899
57. Bell SA, Röcken M, Korting HC (1996) Tinea axillaris, a variant of intertriginous tinea, due to non-occupational infection with *Trichophyton verrucosum*. *Mycoses* 39:471-474
58. Gottlöber P, Jansen T, Peter RU, Korting HC (1997) Perorale Behandlung der Rosacea conglobata mit Isotretinoin: Therapiekontrolle mit der 20 MHz-Sonographie. *Z Hautkrankheiten* 72:24-26
59. Schaller M, Korting HC, Meurer M, Schirren CG (1997) Generalisierte *Mycobacterium avium*-intracelluläre Infektion infolge immunsuppressiver Therapie einer paraneoplastischen Dermatomyositis. *Hautarzt* 48:118-121
60. Gottlöber P, Peter RU, Korting HC (1997) Darstellung der Dermatoheliosis mit der 20 MHz-Sonographie. *Z Hautkrankheiten* 72:526-529
61. Michelsen S, Gottlöber P, Schirren CG, Korting HC (1997) Lichen aureus zosteriformis: Verlaufskontrolle mit der 20 MHz-Sonographie. *Zeitschr Hautkrankh* 72:593-595
62. Jansen T, Kick G, Sakrauski A, Korting HC, Plewig G (1998) Lichen ruber linearis im Verlauf der Blaschko-Linien. *Akt Dermatol* 24:135-139
63. Bastert J, Sing A, Wollenberg A, Korting HC (1998) Aquarium dermatitis: cercarial dermatitis in an aquarist. *Dermatology* 197:84-86
64. Hoegl L, Thoma-Greber E, Röcken M, Korting HC (1998) Shift from persistent oral pseudomembranous to erythematous candidosis in a human immunodeficiency virus (HIV)-infected patient upon combination treatment with an HIV protease inhibitor. *Mycoses* 41:213-217

65. Böhmer U, Korting HC (1998) Relapsing erysipelas mimicking priapism 12 h after coitus. *Sexual Dysfunction* 1:57-58
66. Thomas P, Korting HC, Przybilla (1998): Propolis-induced allergic contact dermatitis mimicking pemphigus vulgaris. *Arch Dermatol (letter)* 134:51-513
67. Ludolph-Hauser D, Michelsen S, Korting HC (1998) Pustulöse Dermatitis nach Anwendung einer zu hoch konzentrierten magistralen Dithranolzubereitung bei seborrhoischem Ekzem. *Hautarzt* 49:781-783
68. Hoegl L, Thoma-Greber E, Röcken M, Korting HC (1998) Persistent oral candidosis by non-albicans *Candida* strains including *Candida glabrata* in a human immunodeficiency virus-infected patient observed over a period of 6 years. *Mycoses* 41:335-338
69. Kick G, Korting HC (1998) Debilitating folliculitis barbae candidomycetica in a trumpeter: successful treatment with fluconazole. *Mycoses* 41:339-342
70. Böhmer U, Gottlöber P, Korting HC (1998) Tinea mammae mimicking atopic eczema. *Mycoses* 41:345-347
71. Kick G, Korting HC (1998) Tinea barbae due to *Trichophyton mentagrophytes* related to persistent child infection. *Mycoses* 41:439-441
72. Böhmer U, Schmid-Wendtner M-H, Korting HC, Kouznetsov AW (1998) The sonographic image of inflamed inguinal lymph nodes in primary syphilis. *Int J STD AIDS* 9:776-777
73. Sizmann N, Korting HC (1999) Prolonged urticaria with 17-1A antibody. *Br Med J* 317:1631
74. Böhmer U, Korting HC (1999) *Trichophyton-rubrum*-Syndrom mit Tinea axillaris als Teilmanifestation. *Hautarzt* 50:292-294
75. Faulhaber D, Korting HC (1999) Tinea capitis et corporis durch *Trichophyton soudanense* bei einer afrikanischen Immigrantenfamilie. *Dtsch Med Wochenschr* 124:589-592
76. Kick G, Schaller M, Korting HC (2000) Late Cutaneous Schistosomiasis Representing an Isolated Skin Manifestation of *Schistosoma mansoni* Infection. *Dermatology* 200:144-146

77. Schaller M, Panhans-Groß A, Bezold G, Korting HC, Wolff H (2000) Ultrastructural defects in acquired immotile sperm flagellae. *Fertil Steril* 73:351-352
78. Vielhauer V, Herzinger T, Korting HC (2000) The sign of Leser-Trélat: a paraneoplastic cutaneous syndrome that facilitates early diagnosis of occult cancer. *Eur J Med Res* 5:512-516
79. Oppel T, Schaller M, Flaig M, Korting HC (2003) Fremdkörpergranulome nach dermalen Injektion eines auf Polymilchsäure basierenden Implantates zur Behandlung von Falten. *JDDG* 1:220-222
80. Thoma-Greber E, Zenker S, Röcken M, Wolff H, Korting HC (2003) Fallbericht Chirurgische Behandlung der Tinea capitis im Kindesalter. *Mycoses* 46:351-354
81. Mühlstädt M, Kerschenlohr K, Scharrer E-M, Pfützner W, Korting HC (2006) Verrucae planae juveniles. Behandlung mit Imiquimod 5% Creme. *Hautarzt* online publiziert

## Review articles

1. Korting HC, Tröscher W, Fallen H (1979) Zur Frage der Herzbeteiligung bei Yersinia-enterocolitica-Infektionen. Herz, Kreislauf 11:28-30
2. Korting HC (1979) Balkanephropathie. Med Klin 74:1371-1374
3. Braun-Falco O, Korting HC (1983) Metronidazoltherapie der Rosazea. Hautarzt 34:261-265
4. Korting HC (1984) Zephalosporin-Allergie und Zephalosporin-Penizillin-Kreuzallergie Eine Übersicht unter besonderer Berücksichtigung für die venerologische Therapie relevanter anaphylaktischer Reaktionen. Hautarzt 35:225-229
5. Korting HC (1985) Urethritis des Mannes; Diagnostik und Therapie. Ther Umsch 42:748-754
6. Braun-Falco O, Korting HC (1986) Der normale pH-Wert der menschlichen Haut. Hautarzt 37:126-129
7. Korting HC (1986) Gonorrhoe und ihre medikamentöse Behandlung. In: Mutschler E, Moser U, Schäfer-Korting M. Aktuelle Pharmakologie, Fortbildungsreihe für Krankenhausapotheker 4: pp 27-34, Dtsch Apotheker-Ztg 126
8. Korting HC, Abeck D (1986) Erreger-Wirtsbeziehungen bei sexuell übertragbaren Krankheiten. Hautarzt 37:547-553
9. Korting HC, Fröschl M (1987) Aktuelle Diagnostik wichtiger sexuell übertragener Erkrankungen: AIDS, Gonorrhoe, nichtgonorrhoeische Urethritis. Hautarzt 38:43-50
10. Korting HC (1987) Unkomplizierte Gonorrhoe und disseminierte Gonokokkeninfektion - Klinik, Diagnostik und Therapie. Urologe (A) 26:237-245
11. Korting HC, Hartinger A (1987) Genitale Chlamydieninfektionen - Klinik, Diagnostik und Therapie. Urologe (A) 26:256-262
12. Zienicke H, Korting HC (1987) Durch Gram-negative Bakterien bedingte Hauterscheinungen bei septischen Krankheiten. Zentralbl Haut 154:75-87

13. Korting HC, Schäfer-Korting M (1988) Pilzerkrankungen und Antimykotika In: Mutschler E, Moser U, Schäfer-Korting M. Aktuelle Pharmakologie, Fortbildungsreihe für Krankenhausapotheker 14: pp 119-127, Dtsch Apotheker-Ztg 128
14. Korting HC, Georgii A (1988) Antimykotikatestung dermato-venerologisch bedeutsamer Hefen: Methoden, Ergebnisse und klinische Relevanz. Hautarzt 39:343-347
15. Ollert M, Korting HC, Braun-Falco O (1988) Pathomechanismus bei Infektionen mit *Candida albicans*. Hautarzt 39:498-503
16. Korting HC, Lukacs A, Braun-Falco O (1988) Mikrobielle Flora und Geruch der gesunden menschlichen Haut. Hautarzt 39:564-568
17. Korting HC, Ollert M, Braun-Falco O (1988) Kandidosen und Dermatophytosen bei HIV-Infektion. Akt Dermatol 14:309-313
18. Schäfer-Korting M, Korting HC (1989) Antimykotika: Pharmakologie und therapeutische Anwendung. Arzneimitteltherapie 7:10-18
19. Behrendt H, Korting HC, Braun-Falco O (1989) Zum Metabolismus von Pharmaka in der Haut. Hautarzt 40:8-14
20. Lukacs A, Korting HC, Braun-Falco O (1989) Antitranspirantien und Deodorantien - Wirkstoffe und Bewertung. Dermatosen Ber Umw 37:53-57
21. Abeck D, Johnson AP, Grimm W, Korting HC, Braun-Falco O (1989) Zur Ätiopathogenese des *Ulcus molle*: Gegenwärtiger Wissensstand - zukünftige Forschungsansätze. Hautarzt 40:407-410
22. Lissner A, Korting HC (1989) Methodik von klinischen Studien bei *Acne vulgaris*. Zentralbl Haut 157:83-93
23. Schäfer-Korting M, Korting HC, Braun-Falco O (1989) Liposome preparations: A step forward in topical drug therapy for skin disease? J Am Acad Dermatol 21:1271-1275
24. Behrendt H, Korting HC (1990) Klinische Prüfung von erwünschten und unerwünschten Wirkungen topisch applizierbarer Glukokortikosteroide am Menschen. Hautarzt 41:2-8

25. Abeck D, Korting HC (1991) Einsatz von Antibiotika bei Hauterkrankungen. *Bayer Int* 11:45-53
26. Herzinger T, Korting HC (1991) In-vitro-Verfahren zur Bewertung der Hautverträglichkeit von Chemikalien, speziell Detergentien. *Dermatosen Ber Umw* 39:117-123
27. Korting HC, Abeck D, Braun-Falco O (1991) Unkomplizierte Gonorrhoe - rationale Therapie heute. *Akt Dermatol* 17:234-239
28. Kerscher M, Korting HC, Schäfer-Korting M (1991) Skin ceramides: structure and function. *Eur J Dermatol* 1:39-43
29. Georgii A, Korting HC (1991) Antifungal susceptibility testing with dermatophytes. *Mycoses* 34:193-199
30. Korting HC, Blecher P, Schäfer-Korting M, Wendel A (1991) Topical liposome drugs to come: What the patent literature tells us. *J Am Acad Dermatol* 25:1068-1071
31. Abeck D, Korting HC (1991) Mechanisms of skin adherence, penetration and tissue necrosis production by *Haemophilus ducreyi*, the causative agent of chancroid. Paul Gerson Unna-Preis: Cutan-mikrobielle Wechselbeziehungen. *Acta Derm Venereol* 174:5-20
32. Korting HC, Schäfer-Korting M (1992) Is Tinea Unguium Still Widely Incurable? A Review Three Decades After the Introduction of Griseofulvin. *Arch Dermatol* 128:243-248
33. Blecher P, Korting HC (1992) Irritative und allergologische Aspekte der Verwendung Altpapier-haltiger Hygienepapiere im Analbereich. *Dermatosen Ber Umw* 40:30-34
34. Kerscher MJ, Korting HC (1992) Treatment of atopic eczema with evening primrose oil: rationale and clinical results. *Clin Investig* 70:167-171
35. Schaich B, Korting HC (1992) Einfluß von Kosmetika und Dermatika auf die Hautlipide. *Hautarzt* 43:403-408
36. Schäfer-Korting M, Korting HC (1992) Ekzeme, Ekzemtherapie heute. *Dtsch Apotheker-Ztg* 132:59-69



37. Korting HC, Kerscher MJ, Schäfer-Korting M (1992) Topical glucocorticoids with improved benefit/risk ratio: Do they exist? *J Am Acad Dermatol* 27:87-92
38. Schaich B, Korting HC, Hollmann J (1993) Hautlipide bei mit Seborrhö und mit Sebostase assoziierten Hauterkrankungen. *Hautarzt* 44:75-80
39. Schmid MH, Korting HC (1993) Liposomes for atopic dry skin: the rationale for a promising approach. *Clin Investig* 71:649-653
40. Korting HC, Kollmann M (1993) Diagnostik und Therapie der Gonorrhoe. *Dtsch Med Wochenschr* 118:1079-1082
41. Kollmann M, Korting HC (1994) Diagnostik und Therapie der Urethritis. *Zeitschr Hautkr* 68:705-710
42. Nachbar F, Korting HC, Plewig G (1994) Zur Bedeutung des positiven Epikutantests auf Lanolin. *Dermatosen Ber Umw* 41:227-236
43. Korting HC (1994) Critical Commentary to "Staphylococcal Scalded Skin Syndrome (SSSS) and Consecutive Septicemia in a Preterm Infant". *Pathol Res Pract* 44:82-83
44. Süss R, Korting HC (1994) Generalised pustular drug rash. *Eur J Dermatol* 5:543-545
45. Hörmann HP, Korting HC (1994) Evidence for the Efficacy and Safety of Topical Herbal Drugs Part I Anti-inflammatory Agents. *Phytomedicine* 1:161-171
46. Korting HC, Kollmann M (1994) Effective single dose treatment of uncomplicated gonorrhoea. *Int J STD AIDS* 5:239-243
47. Schmid M-H, Korting HC (1994) Liposomes: a drug carrier system for topical treatment in dermatology. *Crit Rev Ther Drug Carrier Syst* 11:97-118
48. Nachbar F, Korting HC (1995) The role of vitamin E in normal and damaged skin. *J Mol Med* 73:7-17
49. Herzinger T, Korting HC, Maibach HI (1995) Assessment of Cutaneous and Ocular Irritancy: A Decade of Research on Alternatives to Animal Experimentation. *Fund Appl Toxicol* 24:29-41

50. Thomas PA, Korting HC (1995) The "id"-concept: new insight into an old problem. *Eur J Dermatol* 5:114-116
51. Schmid M-H, Korting HC (1995) The Concept of the Acid Mantle of the Skin: Its Relevance for the Choice of Skin Cleansers. *Dermatology* 191:276-280
52. Schaller M, Korting HC (1996) Interaction of liposomes with human skin: the role of the stratum corneum. *Adv Drug Deliver Rev* 18:303-309
53. Schmid M-H, Korting HC (1996) Therapeutic progress with topical liposome drugs for skin disease. *Adv Drug Delivery Rev* 18:335-342
54. Hoegl L, Ollert M, Korting HC (1996) The role of *Candida albicans* secreted aspartic proteinase in the development of candidoses. *J Mol Med* 74:135-142
55. Stork K, Korting HC, Schäfer-Korting M (1996) Glucocorticoide bei Ekzem und Psoriasis In-vitro-Modelle zur Untersuchung erwünschter und unerwünschter Wirkungen. *Dtsch Apoth Ztg* 136:1657-1662
56. Korting HC, Braun-Falco O (1996) The effect of detergents on skin pH and its consequences. *Clin Dermatol* 14:23-27
57. Schäfer-Korting M, Schmid M-H, Korting HC (1996) Topical Glucocorticoids with Improved Risk-Benefit Ratio Rationale of a New Concept. *Drug Safety* 14:375-385
58. Schmid M-H, Korting HC (1996) Coal tar, pine tar and sulfonated shale oil preparations: comparative activity, efficacy and safety. *Dermatology* 193:1-5
59. Schäfer-Korting M, Blechschmidt J, Korting HC (1996) Clinical use of nystatin in the prevention of systemic candidosis in patients at particular risk. *Mycoses* 39:329-339
60. Abeck D, Grusek E, Korting HC, Ring J (1996) Onychomykose: Epidemiologie, Pathogenese, Klinik, Mikrobiologie und Therapie. *Dtsch Ärztebl* 93:2027-2032
61. Korting HC, Gottlöber P (1996) Dermatomykosen Effektives Management mit gezielter Diagnostik und Therapie. *TW Dermatologie (KOMPAKT)* 3-7, 10-12
62. Korting HC (1997) Nutzen und Risiken topischer Glucocorticoide. *PZ Dermo-pharmazie* 142:10-14

63. Korting HC, Grundmann-Kollmann M (1997) The hydroxypyridones: a class of antimycotics of its own. *Mycoses* 40:243-247
64. Bastert J, Korting HC (1998) Tinea der freien Haut: Gütegesichertes Management. *Zeitschr Ärztl Fortbildung Qualitätssicherung* 92:181-186
65. Abeck D, Korting HC, Mempel M (1998) Pyodermien. *Hautarzt* 49:243-252
66. Bastert J, Korting HC (1998) Diagnostische Methoden zur Spezies-spezifischen Differenzierung unterschiedlicher Dermatophyten. Möglichkeiten und Grenzen. *Dtsch Med Wschr* 123:499-503
67. Korting HC, Sterry W (1998) Gütegesicherte rationelle Diagnostik und Therapie in der Dermatologie. *Hautarzt* 49:755-761
68. Thoma K, Korting HC, Thoma-Greber E (1998) Kühlwirkung von Topika - Kennt-nisstand und Bestimmungsmöglichkeiten in vivo und in vitro. *Pharmazie* 53:1-11
69. Hoegl L, Korting HC, Klebe G (1999) Inhibitors of aspartic proteases in human diseases: molecular modeling comes of age. *Pharmazie* 54:319-329
70. Niewerth M, Korting HC (1999) Management of Onychomycoses. *Drugs* 58:283-296
71. Chen WC, Schaller M, Korting HC, Januschke E, Karpati S, Plewig G (1999) Introduction to Immune Electron Microscopy Principles, Methods and Applications in Dermatology. *Dermatol Sinica* 17:282-299
72. Niewerth M, Korting HC (2000) The use of systemic antimycotics in dermatotherapy. *Eur J Dermatol* 10:155-160
73. Schackert C, Korting HC, Schäfer-Korting M (2000) Qualitative and Quantitative Assessment of the Benefit-Risk Ratio of Medium Potency Topical Corticosteroids In Vitro and In Vivo. Characterisation of Drugs with an Increased Benefit-Risk Ratio. *Bio Drugs* 13:267-277
74. Korting HC, Schaller M (2000) Neue Entwicklungen in der Mykologie. *Dtsch Ärztebl* 97:A1682-A1684

75. Schorling SR, Korting HC, Frosch M, Mühlischlegel FA (2000) The Role of *Candida dubliniensis* in Oral Candidiasis in Human Immunodeficiency Virus-Infected Individuals. *Crit Rev Microbiol* 26:59-68
76. Kick G, Korting HC, Wüster C, Plewig G (2000) Osteoporose unter Langzeitbehandlung mit Glukokortikoiden – Bisphosphonate zur Prävention und Therapie. *Zschr Hautkr* 10:575-580
77. Korting HC, Schaller M (2001) Neue Entwicklungen in der Medizinischen Mykologie. *Hautarzt* 52:91-97
78. Bastert J, Schaller M, Korting HC, Evans EGV (2001) Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts. *Int J Antimicrob Ag* 17:81-91
79. Korting HC, Kilburg A, Rychlik R (2001) 1%ige Terbinafin-Creme zur Kurzzeittherapie bei *Tinea pedis*. Selbstmedikation mit hoher Effizienz. *Dtsch Apotheker-Ztg* 141:3428-3432
80. Niewerth M, Korting HC (2001) Phospholipases of *Candida albicans*. *Mycoses* 44:1-8
81. Unholzer A, Korting HC (2002) High-frequency ultrasound in the evaluation of pharmacological effects on the skin. *Skin Pharmacol Appl Skin Physiol* 15:71-84
82. Mägert HJ, Kreutzmann P, Drögemüller K, Ständker L, Adermann K, Walden M, John H, Korting HC, Forssmann WG (2002) The 15-domain serine proteinase inhibitor LEKT1: Biochemical properties, genomic organization, and pathophysiological role. *Eur J Med Res* 7:1-8
83. Bein M, Schaller M, Korting HC (2002) The secreted aspartic proteinases as a new target in the therapy of candidiasis. *Curr Drug Targets* 3:351-357
84. Niewerth M, Korting HC (2002) *Candida albicans* and the principle of opportunism An essay. *Mycoses* 45:253-258
85. Möhrenschrager M, Korting HC, Seidl HP, Ring J, Abeck D (2002) *Tinea capitis* Therapieoptionen im Post-Griseofulvin-Zeitalter. *Hautarzt* 53:788-794
86. Korting HC (2003) Total quality management in dermato-mycology in Germany. *Mycoses* 46:2-4

87. Korting HC (2003) Haut- und Schleimhautmykosen und ihre Therapie. Pharm Unserer Zeit 32:130-137
88. Oppel T, Korting HC (2003) Onychodystrophy and its management. German Medical Science 1:Doc02
89. Roeder A, Kirschning CJ, Rupec RA, Schaller M, Korting HC (2004) Toll-like receptors and innate antifungal responses. Trends Microbiol 12:44-49
90. Oppel T, Korting HC (2004) Actinic Keratosis: The Key Event in the Evolution from Photoaged Skin to Squamous Cell Carcinoma. Therapy Based on Pathogenetic and Clinical Aspects. Skin Pharmacol Physiol 17:67-76
91. Korting HC, Kresimon J, Rychlik R (2004) Vergleichende Bewertung der Wirkung und klinischen Wirksamkeit von terbinafinhaltigen und bifonazolhaltigen Topika bei der Behandlung der Fußmykose. Akt Dermatol 30:210-217
92. Roeder A, Schaller M, Schäfer-Korting M, Korting HC (2004) Tazarotene: Therapeutic Strategies in the Treatment of Psoriasis, Acne and Photoaging. Skin Pharmacol Physiol 17:111-118
93. Merk K, Borelli C, Schaller M, Korting HC (2004) Laktobazillen als Probiotika zur Behandlung urogenitaler und intestinaler Infektionen sowie zur Vorbeugung und Therapie von allergischen Erkrankungen. JDDG 2:752-757
94. Roeder A, Schaller M, Schäfer-Korting M, Korting HC (2005) Safety and Efficacy of Fluticasone Propionate in the Topical Treatment of Skin Diseases. Skin Pharmacol Physiol 18:3-11
95. Schneider JJ, Unholzer A, Schaller M, Schäfer-Korting M, Korting HC (2005) Human defensins. J Mol Med 83:587-595
96. Merk K, Borelli C, Korting HC (2005) Lactobacilli – bacteria-host interactions with special regard to the urogenital tract. Int J Med Microbiol 295: 9-18
97. Schäfer-Korting M, Kleuser B, Ahmed M, Höltje H-D, Korting HC (2005) Glucocorticoids for Human Skin: New Aspects of the Mechanism of Action. Skin Pharmacol Physiol 18:103-114

98. Korting HC (2005) Erhaltungsbehandlung und Frühintervention – Das neue Paradigma beim Management des atopischen Ekzems. JDDG 3:519-523
99. Maier T, Korting HC (2005) Anwendungen von Dermatika in der Schwangerschaft. Gynäkologe 38:780-790
100. Maier T, Korting HG (2005) Sunscreens – Which and What for? Skin Pharmacol Physiol 18:253-262
101. Weindl G, Schäfer-Korting M, Schaller M, Korting HC (2005) Peroxisome Proliferator-Activated Receptors and their Ligands. Entry Into the Post-Glucocorticoid Era of Skin Treatment? Drugs 14:1919-1934
102. Schaller M, Borelli C, Korting HC, Hube B (2005) Hydrolytic enzymes as virulence factors of *Candida albicans*. Mycoses 48: 365-377
103. Ruge E, Korting HC, Borelli C (2005) Current state of three-dimensional characterisation of antifungal targets and its use for molecular modelling in drug design. Int J Antimicrob Agents 26:427-441
104. Otte N, Borelli C, Korting HC (2005) Nicotinamide – biologic actions of an emerging cosmetic ingredient. Int J Cosmet Sci 27:255-261
105. Maier T, Korting HC (2006) Dermatika in der Schwangerschaft. Pharm Ztg 17:1561-1572
106. Beifuß B, Borelli C, Korting HC (2006) Mykologisches Labor. Hautarzt 57:487-492
107. Schmid-Wendtner M-H, Korting HC (2006) The pH of the Skin Surface and Its Impact on the Barrier Function. Skin Pharmacol Physiol 19:296-302
108. Pavicic T, Korting HC (2006) Xerosis and callus formation as a key to the diabetic foot syndrome: dermatologic view of the problem and its management. JDDG 4:935-941
109. Pavicic T, Borelli C, Korting HC (2006) Cellulite – das größte Hautproblem des Gesunden? Eine Annäherung. JDDG 4:861-870

110. Weindl G, Roeder A, Schäfer-Korting M, Schaller M, Korting HC (2006)  
Receptor-selective retinoids for psoriasis: focus on tazarotene. Am J Clin  
Dermatol 7:85-97